 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016      COVER PAGE  
     
DCP Protocol #:  UAZ2017 -09-02  
Local Protocol #:  1711022046   
 
Clinical Study of Avmacol®  for Detoxification of Tobacco Carcinogens in Heavy Smokers  
  
Consortium Name:    The University of Arizona Early Phase Cancer Prevention Consortium   
Name of Consortium Principal  H-H Sherry Chow, PhD  
Investigator:     University of Arizona Cancer Center  
     1515 N. Campbell Ave.  
     Tucson, AZ 85724  
Telephone: (520) 626 -3358; Fax: (520) 626 -5348  
schow@email.arizona.edu  
 
Organization Name:    University of Arizona   
Protocol Principal Investigator:  Julie E. Bauman , MD , MPH  
  The University of Arizona, Arizona Cancer Center  
  1515 N. Campbell Ave., Tucson, AZ 85724  
Telephone (520) 626-5972 ; Fax (520) 626 -2225  
  jebauman@email.arizona.edu  
 
Organization:     University of Arizona  
Statistician:     Paul Hsu, PhD  
     The University of Arizona Cancer Center  
 1515 N. Campbell Ave.  
 Tucson, AZ 85724  
 Telephone: (520) 626 -5054; Fax: (525) 626-2767  
 pchhsu@email.arizona.edu  
 
Medical Monitor:  Eva Szabo , MD  
  Medical Officer and Chief  
  Lung & Upper Aerodigestive Cancer Research Group  
  Division of Cancer Prevention, NCI, NIH  
  9609 Medical Center Dr.  
  Rockville, MD 20850  
Tel: (240) 276 -7011; FAX: (240) 276 -7848  
  Email:  szaboe@mail.nih.gov    
 
IND Sponsor:   NCI/Division of Cancer Prevention   
 
IND#   
 
Agent(s)/Supplier :  Avmacol®  /Nutramax     
 
NCI Contract #   HHSN2612012000311  
 
Protocol Version Date:    10.17.18 
 
Protocol Revision or   
Amendment #    Version 3, Amendment 6 

 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  SCHE MA 
 
Clinical Study of Avmacol® for Detoxification of Tobacco Carcinogens in Heavy Smokers  
 
Current smokers with ≥ 20 pack years self-reported smoking history and a current average use of ≥ 10 cigarettes/day  
 
 
Visit 1 : Screening  
Informed consent, clinical evaluation (medical history, vital signs, brief physical exam), clinical labs, conmeds and supplement use, 
Karnofsky performance status, baseline tobacco /alcohol  assessment , pregnancy test (if applicable)  
 
Randomization  
High -Low Arm or Low -High Arm  
 
Visit 2 : Baseline Specimen Collection for Intervention Period 1  
Collection of buccal cells, nasal brushing and blood , AEs, conmeds, current tobacco use, pregnancy test (if applicable),   
ensure overnight urine collection, dispense study agent  
 
Intervention Period 1 (10 -14 days)  
High -Low Arm: 8 tablets Avmacol® per day or Low-High Arm: 4  tablets of Avmacol® per day 
 
 
Visit 3 : Interim Visit ( Intervention Period 1, (may occur on Day 4 to Day 8 ) 
Collection of buccal cells, AEs, conmeds, current tobacco use   
 
 
Visit 4 : End-of-Intervention Period 1 Visit  
Collection of buccal cells, nasal brushing and blood,  AEs, conmeds, current tobacco use, ensure overnight urine collection,  
study agent return , compliance  
 
Washout Period (10 -14 days)  
 
Visit 5 : Baseline Specimen Collection for Intervention Period 2  
Collection of buccal cells, nasal brushing and blood, AEs, conmeds, current tobacco use , pregnancy test (if applicable),  
ensure overnight urine collection, dispense study agent  
 
Intervention Period 2 (10 -14 days)  
High -Low Arm: 4 tablets Avmacol® per day or Low -High Arm: 8 tablets of Avmacol® per day 
 
 
Visit 6 : Interim Visit ( Intervention Period 2 , (may occur on Day 4 to Day 8 )) 
Collection of buccal cells, AEs, conmeds, current tobacco use  
 
 
Visit 7 : End-of-Intervention  Period 2  Visit  
Collection of buccal cells, nasal brushing and blood, AEs, conmeds, follow -up tobacco /alcohol  assessment,  
ensure overnight urine collection, study agent return,  compliance,  clinical labs  
 
 
Endpoints  
Urinary tobacco carcinogens  
Buccal cell N RF target gene  transcripts  and nuclear morphometry  
GSTM1 and GSTT1 genoty ping  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  TABLE OF CONTENTS  
 
COVER PAGE  ................................ ................................ ................................ ................................ ..............  0 
SCHEMA  ................................ ................................ ................................ ................................ ......................  1 
1. OBJECTIVES  ................................ ................................ ................................ ................................ ..... 4 
1.1 Primary Objective  ................................ ................................ ................................ ................................ ........ 4 
1.2 Secondary Objectives  ................................ ................................ ................................ ................................ ...4 
1.3 Exploratory Objectives  ................................ ................................ ................................ ................................ 4 
2. BACKGROUND  ................................ ................................ ................................ ................................ . 4 
2.1 Tobacco -related Head and Neck Cancer  ................................ ................................ ................................ ......4 
2.2 Avmacol®  ................................ ................................ ................................ ................................ .................... 5 
2.3 Rationale  ................................ ................................ ................................ ................................ ...................... 6 
3. SUMMARY OF STUDY PLAN  ................................ ................................ ................................ ........  6 
4. PARTICIPANT SELECTION  ................................ ................................ ................................ ............  8 
4.1 Inclusion Criteria  ................................ ................................ ................................ ................................ ......... 8 
4.2 Exclusion Criteria  ................................ ................................ ................................ ................................ ........ 9 
4.3 Inclusion of Women and Minorities ................................ ................................ ................................ ............. 9 
4.4 Recruitment and Retention Plan  ................................ ................................ ................................ ................... 9 
5. AGENT ADMINISTRATION  ................................ ................................ ................................ ............  9 
5.1 Dose Regimen and Dose Groups  ................................ ................................ ................................ ................. 9 
5.2 Avmacol® Administration  ................................ ................................ ................................ .........................  10 
5.3 Run-in Procedures  ................................ ................................ ................................ ................................ ...... 10 
5.4 Contraindications  ................................ ................................ ................................ ................................ ....... 10 
5.5 Concomitant Medications  ................................ ................................ ................................ ..........................  10 
5.6 Dose Modification ................................ ................................ ................................ ................................ ...... 10 
5.7 Adherence/Compliance  ................................ ................................ ................................ ..............................  10 
6. PHARMACEUTICAL INFORMATION  ................................ ................................ .........................  11 
6.1 Avmacol®  (IND information pending)  ................................ ................................ ................................ ..... 11 
6.2 Reported Adverse Events and Potential Risks  ................................ ................................ ...........................  11 
6.3  Availability  ................................ ................................ ................................ ................................ ................  15 
6.4 Agent Distribution ................................ ................................ ................................ ................................ ...... 15 
6.5  Agent Accountability  ................................ ................................ ................................ ................................ . 15 
6.6 Packaging and Labeling  ................................ ................................ ................................ .............................  15 
6.7 Storage  ................................ ................................ ................................ ................................ .......................  15 
6.8 Registration/Randomization  ................................ ................................ ................................ .......................  15 
6.9 Blinding and Unblinding Methods  ................................ ................................ ................................ .............  16 
6.10 Agent Destruction/Disposal  ................................ ................................ ................................ .......................  16 
7.1 Schedule of Events  ................................ ................................ ................................ ................................ ..... 17 
7.2 Screening Evaluation  ................................ ................................ ................................ ................................ . 18 
7.3 Evaluation During Study Intervention  ................................ ................................ ................................ ....... 18 
7.4 Evaluation at Completion of Study Intervention  ................................ ................................ ........................  20 
7.5 Post-intervention Follow -up Period  ................................ ................................ ................................ ...........  20 
7.6 Methods for Clinical Procedures  ................................ ................................ ................................ ................  20 
8.  CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION  ................................ ...............  20 
8.1 Primary Endpoint  ................................ ................................ ................................ ................................ ....... 20 
8.2 Secondary Endpoints ................................ ................................ ................................ ................................ .. 21 
8.3 Off-Agent Criteria  ................................ ................................ ................................ ................................ ...... 21 
8.4 Off-Study Criteria  ................................ ................................ ................................ ................................ ...... 21 
8.5 Study Termination ................................ ................................ ................................ ................................ ...... 22 
9. CORRELATIVE/SPECIAL STUDIES  ................................ ................................ ............................  22 
9.1 Rationale for Methodology Selection  ................................ ................................ ................................ ........  22 
9.2 Comparable Methods  ................................ ................................ ................................ ................................ . 22 
10. SPECIMEN MANAGEMENT  ................................ ................................ ................................ .........  22 
10.1 Laboratories  ................................ ................................ ................................ ................................ ...............  22 
10.2 Colle ction and Handling Procedures  ................................ ................................ ................................ ..........  23 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  10.3 Shipping Instructions  ................................ ................................ ................................ ................................ . 23 
10.4 Tissue Banking  ................................ ................................ ................................ ................................ ...........  24 
11. REPO RTING ADVERSE EVENTS  ................................ ................................ ................................ . 24 
11.1 Adverse Events  ................................ ................................ ................................ ................................ ..........  24 
11.2 Serious Adverse Events  ................................ ................................ ................................ .............................  25 
12. STUDY MONITORING  ................................ ................................ ................................ ...................  26 
12.1 Data Management  ................................ ................................ ................................ ................................ ...... 27 
12.2 Case Report Forms  ................................ ................................ ................................ ................................ ..... 27 
12.3 Source Documents  ................................ ................................ ................................ ................................ ..... 27 
12.4 Data and Safety Monitoring Plan  ................................ ................................ ................................ ...............  27 
12.5 Sponsor or FDA Monitoring  ................................ ................................ ................................ ......................  27 
12.6 Record Retention  ................................ ................................ ................................ ................................ ....... 27 
12.7 Cooperative Research and Development Agreement (CRADA)/Clinical Trials Agreement (CTA)  .........  28 
13. STATISTICAL CONSIDERATIONS  ................................ ................................ ..............................  28 
13.1 Study Design/Description  ................................ ................................ ................................ ..........................  28 
13.2 Randomization/Stratification  ................................ ................................ ................................ .....................  28 
13.3 Accrual and Feasibility  ................................ ................................ ................................ ..............................  28 
13.4 Primary Objective, Endpoint(s), Analysis Plan ................................ ................................ ..........................  28 
13.5 Secondary Objectives, Endpoints, Analysis Plans  ................................ ................................ .....................  28 
13.6 Reporting  and Exclusions  ................................ ................................ ................................ ..........................  29 
13.7 Evaluation of Toxicity  ................................ ................................ ................................ ...............................  29 
13.8 Evaluation of Response  ................................ ................................ ................................ ..............................  29 
13.9 Interim Analysis  ................................ ................................ ................................ ................................ .........  29 
13.10  Ancillary Studies  ................................ ................................ ................................ ................................ ........  30 
14. ETHICAL AND REGULATORY CONSIDERATIONS  ................................ ................................  30 
14.1 Form FDA 1572  ................................ ................................ ................................ ................................ .........  30 
14.2 Other  Required Documents  ................................ ................................ ................................ ........................  30 
14.3 Institutional Review Board Approval  ................................ ................................ ................................ ........  30 
14.4 Informed Consent  ................................ ................................ ................................ ................................ ....... 30 
14.5 Submission of Regulatory Documents  ................................ ................................ ................................ ....... 31 
14.6 Other  ................................ ................................ ................................ ................................ ..........................  31 
15. FINANCING, EXPENSES, AND/OR INSURANCE  ................................ ................................ ...... 31 
REFERENCES  ................................ ................................ ................................ ................................ ...........  32 
CONSENT FORM  ................................ ................................ ................................ ................................ ...... 36 
APPENDIX A  ................................ ................................ ................................ ................................ .............  46 
APPENDIX B  ................................ ................................ ................................ ................................ .............  47 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  1. OBJECTIVES  
 
1.1 Primary Objective   
To determine whether Avmacol® increases the urinary excretion of the mercapturic acid of the tobacco 
carcinogen, benzene , in healthy volunteers who are current heavy smokers .  
 
1.2 Secondary Objectives   
• To determine whether Avmacol® increases the urinary excretion o f the mercapturic acids of other  
tobacco carcinogens,  including  acrolein and crotonaldehyde ;  
• To determine whether Avmacol® increases the urinary excretion o f the mercapturic acids of tobacco 
carcinogens , normalized by bio-measurement of tobacco exposure;   
• To determine whether Avmacol® upregulates the NRF2 target gene transcripts  in the buccal cells  of 
current smokers;  
• To evaluate for a dose -response relationship between Avmacol® and the deto xification of tobacco 
carcinogens  and the expression of NRF2 target gene transcripts . 
• To determine  the relationship between systemic study agent exposure  and biomarker modulation .  
 
1.3 Exploratory Objectives  
• To determine whether the GSTM1  and GSTT1  genotypes are important genetic modulators of 
detoxi fication of tobacco carcinogens  with Avmacol® treatment ; 
• To bank specimens for future research including evaluation  of tobacco gene signatures in buccal and 
nasal epithelium  and buccal cell nuclear morphometry . 
 
 
2. BACKGROUND  
 
2.1 Tobacco -related Head and Neck Cancer  
 
Long -term success in the treatment of tobacco -related head and neck squamous cell carcinoma (HNSCC) is hindered by 
an alarming rate of second primary tumor (SPT) formation following curative treatment. Patients with human 
papillomavirus (HPV) -negative HNSC C develop a SPT of the upper aerodigestive tract at the rate of 3 -6% per year, and 
are most likely to succumb to these secondary cancers (1-4). Although smoking cessation reduces the occurrence of SPTs, 
moder ation of risk is not observed for 5 years, and is insufficient to return risk to baseline (3, 5) . Moreover, although 70% 
of smokers a ttempt to quit annually, tobacco cessation is unsuccessful in the majority due to the power of nicotine 
addiction, and recidivism occurs in approximately 90% (6). Thus, most tobacco users are unable or unwilling to quit, and 
those who do succeed still face chronic exposure to the endogenous carcinogens of metabolism or the exogenous 
carcinogens of industrializa tion.  
 
The concept of “condemned mucosa”, or epithelial field cancerization from chronic exposure to environmental 
carcinogens, first raised the possibility of chemoprevention for HNSCC in 1953 (7); however, no nontoxic, effective 
chemopreventive agent has been identified. When epidemiologic studies found that reduced risk for both HNSCC and 
SPTs is associated with diets rich in fruits and vegetables (8-12), the first chemoprevention strategies focused on 
pharmacologic doses of derivative micronutrients . Preclinical models supported retinoids, synthetic vitamin A analogues, 
as modulators of oral environmental carcinogenesis (13, 14) . Although high dose isotretinoin reversed oral premalignant 
lesions (OPL s) (15) and prevented SPTs in a landmark Phase III HNSCC chemoprevention study (16), substantial toxicity 
precluded chronic administration and SPT incidence reverted to baseline within 3 years. A subsequent trial of low dose 
isotretinoin was tolerable but ineffective (17). Molecular targeting of EGFR or COX -2 has shown preclinical 
chemopreventive efficacy against oral cancer (18-22), but clinical application has been hampered by poor efficacy and 
tolerability in humans (23-27). Thus,  a tremendous unmet need remains for an effective and well -tolerated 
chemopreventive agent against tobacco -related HNSCC and SPTs.  
 
UAZ2017 -09-02 
Protocol Version 3 Amendment 6, 10.17.18 
2.2 Avmacol® 
Epidemiologi c studies report that reduced risk for both HNSCC and SPTs is associated with diets rich in the Brassica 
fam
ily of cruciferous vegetable s (8-12). Broccoli extract potently induces cytoprotective enzymes (28), which mitigate the 
effects of environmental carcinogens including benz ene, aldehydes and polycyclic aromati c hydrocarbons found in 
tobacco smoke by enha ncing their detoxicati on (29, 30). Mor e than 80% of inducer activity is driven by the 
phytochemical sulforaphane (SF), produced when its precursor glucoraphani n (GR) is hy drolyzed by myrosinase during 
food preparation or chewing (31). Mechanistically, SF disrupts the polyubiquitinati on of the NR F2 t ranscription factor 
mediated by its inhibitory protein, KEA P1. Thi s free s NRF2 to translocate t o the nucleus and bind to anti-oxidant 
response elements (AREs) in the promoter regions of target genes (32, 33). As GR is 20-50 times more concentrat ed in 
broccoli seeds relative to mature plant s (31, 34), we are developing broccoli seed preparations (BSPs) as a 
chemopreventive agent against carcinogen-induced cancers, a nd hav e determined the safety and pharmacokinetics (PK) of 
various BS Ps in humans (33, 35-39).  
Two types of highly standardiz ed, lyophilized boiling water extracts of 3-day-old broccoli sprouts have be en devel oped by 
our collaborator s (J. Fahey, P. Talalay) at the Johns Hopkins Cullman Chemoprotection Institut e under GMP conditions, 
and used extensively unde r clinical protocol s – including our own pilot study evaluating the oral bioactivity of broccoli 
sprout extracts (BSE) in the oral mucosa of healthy volunteers ([STUDY_ID_REMOVED]) (39). However , there ar e three main 
problems in achieving consistent delivery and bioavailability of active SF by means of lyophilized BS E: (1) SF is only 
moderately storage- and heat-stable over time, especially in aque ous solution.  (2) SF-rich BSE powder s are extremely 
hygroscopic and the preparation of capsules containing accurate dose s by weight is challenging and very expensive. (3) 
Administration of GR as an oral precursor of SF results in highly variable conv ersions of GR to SF metabolites 
(dithiocarbamates) among individual s, ranging from 1 – 40% (35, 38, 40-42). Moreover, the curated GMP manufacturing 
process for BSEs is laborious a nd expensive, and consequently BSE is no l onger availabl e for clinical investigation. 
Avmacol ® is a commercially available dietary supp lement that contains GR plus the fully active enzym e myrosinase, thus 
yielding a higher and more consistent dose of SF upon ingesti on. Avmacol® tablets contain only GR-rich broccoli seed 
extract, freeze-dried broccoli sprout s for the myrosinase source , and t he inert excipient s required to form a tablet. 
Avmacol® is manufactured by Nutramax Laboratories, Inc., has be en sol d as a nutritional supplement in the United States 
since 2013, and is manufactured under GMP standards. The coated tablet s contain 12.5 mg of GR, and have a minimum 
shelf life of 30 months at ambient temperature. We have completed a healthy volunteer study confirming the 
bioavailability of SF when delivered a s Avmacol ®  ([STUDY_ID_REMOVED]), and thi s dietary suppl ement is now under 
investigati on as a chemoprevention agent in multiple disease context s, including the detoxication of air pollutant s in 
Qidong, China (Kensler).  
 
DCP Protocol Template Version 8.5 
08/31/2016 
UAZ2017 -09-02 
Protocol Version 3 Amendment 6, 10.17.18 
DCP Protocol Template Version 8.5 
08/31/2016  2.3 Rationale  
Proof -of-concept clinical trials in healthy volunteers have shown that BSPs rich in GR and/or SF are well -tolerated and 
promote rapid, sustained detoxication of the airborne pollutants acrolein and benzene (33, 35 -38). In preclinical studies, 
SF has exhibited chemopreventive activity against carcinogen -induced stomach, skin and breast cancers (43-47). Studies 
in Nrf2-/- mice have shown that the chemopreventive effect of sulforaphane against benzo[a]pyrene -induced gastric cancer 
and 7,12 -dimethylbenz( a)anthracene (DMBA) -induced skin cancer depends on th e NRF2 signaling pathway (43, 44, 47) . 
The relevance of NRF2 to oral cancer chemoprevention is highlighted by the enhanced susceptibility of Nrf2-/- mice to 
oral cancer induced by the carcinogen 4 -nitroquinoline -1-oxide (4NQO), and the reduced susceptibility of Keap1-/- mice 
(48). We have shown that SF induces NRF2 and NRF2 target gene expression in normal oral keratinocytes and in HNSCC 
cell lines in vitro . In a preclinical chemoprevention study, we have determined that SF reduces both the incidence and 
total burden of oral tumors in 4NQO -treated mice.  Finally, we have observed mucosal bioactivity of two well -tolerated 
BSPs,  sulforaphane -rich BSE and Avmacol® ((39); unpublished data [STUDY_ID_REMOVED]), which both upregulated transcripts 
for the NRF2 target gene NQO1  in the buccal mucosa of healthy volunteers.  
2-Phenethyl isothiocyanate (PEITC), another glucosinolate present in certain cruciferous vegetables including wat ercress 
and broccoli sprouts, has been demonstrated to have multiple chemoprotective effects on xenobiotic metabolizing 
enzymes and molecular pathways related to cancer (1, 2).  In a randomized, crossover study, PEITC promoted detoxication 
of benzene and ac rolein in a healthy smoking population (49). A much stronger effect was observed among subjects with 
the null genotype of both GSTM1  and GSTT1 . Due to established mechanisms of action, SF -rich BSPs are likely to be 
more effective inducers of NRF2 target genes and consequent detoxication of tobacco carcinogens in this population. 
Moreover, in a 300 -patient study in Qidong, China, the upregulation  of the urinary excretion of the mercapturic acid of 
benzene by broccoli sprout extracts was independent of GSTM1  and GSTT1  genotypes, suggesting broader applicability of 
this green chemoprevention strategy across a general population  (38). 
In the proposed trial, we aim to evaluate the pharmacodynamic activity of Avmacol® in healthy current heavy smokers . 
The primary objective is to determine whether Avmacol®  increases the urinary excretion of the mercapturic acid of the 
tobacco carcinogen , benzene  in healthy volunteers who currently smoke. Secondary objectives include: 1) to determine 
whether Avmacol®  increases the urinary excretion of the mercapturic acids the tobacco carcinogens,  acrolein , and 
crotonaldehyde ; 2) To evaluate for a dose -response relationship between Avmacol®  and the detoxification of tobacco 
carcinogens and the expression of NRF2 target gene transcripts ; 3) to determine whether NRF2 target genes are 
upregulated i n the mucos a of current smokers. Exploratory objectives include: 1) to determine whether the GSTM1  and 
GSTT1  genotypes are important genetic modulators of detoxication of tobacco carcinogens  during Avmacol® treatment ; 
2)to bank biospecimens for future study, including the evaluation of  tobacco gene signatures in buccal and nasal
epithelium , as well as buccal cell nuclear morphometry .
Increasing evidence suggests that tobacco and alcohol use are risk factors in the development of intraepithelial neoplasia 
and cancer. In addition, tobacco and alcohol use may adversely affect agent intervention, for example by altering the 
safety profile or metabolism of a drug. Standardized assessments of tobacco and alcohol use during clinical trials will aid 
in understanding t he potential relationship between the use of these products and clinical endpoints or cancer prevention 
biomarkers. Therefore, NCI, DCP is including a ssessment of tobacco and alcohol use at baseline and  at the End of 
Intervention visit,  to determine the po tential impact of tobacco and alcohol use on  1) treatment toxicity and symptom 
burden , and 2) the efficacy of treatment intervention.   
3. SUMMARY OF STUDY PLA N
This is a n open -label , randomized, cross -over study, evaluating whether two different doses of  Avmacol®  (4 tablets  per 
day for 10-14 days; 8 tablets  per day for 10-14 days) increase the detoxi fication of tobacco carcinogens in otherwise 
healthy, current heavy smokers. Participants will serve as their own controls.  We chose the open -label design be cause the 
study endpo ints are not likely to be affected by the knowledge of the dosage assignment. We believe that the proposed 
randomized cross -over design would minimize the potential bias from the open -label design.  We plan to accrue 61 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  eligible participants to initiate agent intervention. With an anticipated attrition rate of 33% or less (with respect to 
completing the intervention and having complete endpoint data), we expect to have at least 41 participants with evaluable 
endpoint data . Projected accrual is 2 participants per month.  
 
Participants will undergo a screening evaluation (Visit 1) in which the informed consent form will be signed. Participants 
will be assessed for study eligibility . Detailed inclusion and exclusion criteria are listed in sections 4.1 and 4.2 . All 
participants will undergo evaluation  to obtain height, weight, blood pressure, pulse, tem perature measurements, a brief 
physical exam consisting of an examination of the heart, lungs and abdomen, and Karnofsky  perfor mance status 
assessment. They will also be evaluated for concurrent medication and supplement use, baseline tobacco/alcohol 
assessment , medical history, and labora tory analysis with complete blood count  with differential  (CBC -diff), 
comprehensive metabolic  panel (CMP) . Women of childbearing capacity will have a urine pregnancy test. Study 
participants will be provided with a daily diary for recor ding any adverse events (AEs) and medication usage  and a urine 
collection kit (an overnight urine collection container, a collection hat, and instructions for collecting overnight urine) t o 
be used the night prior to Visit 2.  
 
 Once determined eligible, participants will be randomized (1:1) to one of the  following arms: High -Low Arm ( 8 tablets 
Avmacol® per day during I ntervention Period 1 an d 4 tablets Avmacol® per day during Intervention P eriod 2) and Low -
High Arm ( 4 tablets Avmacol® per day during I ntervention period 1 an d 8 tablets Avmacol® per day dur ing Intervention 
Period 2).   
 
Participants will return to the clinic for Baseline Specimen Collection for Intervention Period 1  (Visit 2) . Participants will 
be contacted prior to the visit to remind them to collect overnight urine the night prior to Visit 2. Participants will bring 
the overnight urine to the clinic and undergo baseline specimen collection for the collection of buccal cells ( for NRF 
target gene transcripts), nasal brushing (banked for gene expression an alysis) and blood (for genotyp ing and b anking) . 
Participants will be assessed for baseline symptoms , concomitant medications, and be queried on current  tobacco use. 
Urine pregnancy test will be repeated, if applicable.  Those who miss the overnight urine collection prior to Visit 2 will be 
asked to collect overnight urine the night of the visit and return the urine to the clinic the following day. Participants will 
be provided with Avmacol® pills for Intervention Period 1 after confirmation of overnight urine collection. Participants 
will be pro vided with an Intake Calendar for recording agent intake.  
 
During Intervention Period 1 (10 -14 days), participants in the High -Low Arm will take 8 tablets of Avmacol®  each day 
and participants in the Low -High Arm will take 4 tablets of Avmacol  each day. Participants will be instructed to take the 
Avmacol®  pills with the evening meal.  Day 1 of the Intervention Period 1 begins the day the first dose is taken. During 
Intervention Period 1, p articipants will return to the clinic on Day  4, 5, 6, 7, or 8 for an Interim Visit (Visit 3). Participants 
will undergo the collection of buccal cells  and be assessed f or AEs, concomitant medications  and be queried on current 
tobacco use . Participants will be provided with a new urine collection kit  to be used t he night prior to Visit 4 . 
 
Participants will return to the clinic at the end of Intervention Period 1 (Visit 4). Participants will be contacted prior to this 
visit to remind them to collect overnight urine the night prior to Visit 4. Participants will bring the overnight urine to 
clinic, return unused pill s, undergo specimen collection for the collection of buccal cells, nasal brushing and blood . 
Participants will also be  assessed for AEs, concomitant medications, compliance, and be queried on current toba cco use . 
Those who miss the overnight urine collection prior to Visit 4 will be provided with additional Avmacol®  pills and be 
asked to  take the pills the evening of Visit 4 and  collect overnight urine the night of the visit and return the urine to the 
clinic the following day. Participants will be provided with a new urine collection kit  to be used the night prior to Visit 5 . 
 
Participants will undergo a Washout Period (10 -14 days) after completing Intervention Period 1. After the Washout 
Period, particip ants will return to the clinic (Visit 5) to undergo baseline specimen collection for Intervention Period 2 .  
Participants will be contacted prior to the visit to remind them to collect overnight urine the night prior to Visit 5. 
Participants will bring the  overnight urine to the clinic and undergo baseline specimen collection for the collection of 
buccal cells, nasal brushing and blood. Participants will also be assessed for AEs, concomitant medications, and be 
queried on current tobacco use. Urine pregnanc y test will be repeated, if applicable. Those who miss the overnight u rine 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  collection prior to Visit 5  will be asked to collect overnight urine the night of the visit and return the urine to the clinic the 
following day. Participants will receive Avmacol® pills for Intervention Period 2 after the overnight urine collection is 
confirmed.   
 
During Intervention Period 2 (10 -14 days), participants in the High -Low Arm will take 4 tablets of Avmacol® each day 
and participants in the Low -High Arm will take 8 tablets of Avmacol® each day. Participants will be instructed to take the 
Avmacol® pills with the evening meal.  Participants will be provided with an Intake Calendar for recording agent intake.  
Day 1 of the Intervention Period 2 begins the day the first dose is taken. During Intervention Period 2, participants will 
return to the clinic on Day  4, 5, 6, 7, or 8  for an Interim Visit (Visit 6).  Participants will undergo the collection of buccal 
cells and be assessed f or AEs, concomitant medications  and be queried on current tobacco use . Participants will be 
provided with a new urine collection kit to be used t he night before Visit 7.  
 
Participants will return to the clinic at the end of Intervention Per iod 2 (Visit 7). Participants will be contacted prior to the 
visit to remind them to collect overnight urine the night prior to Visit 7. Participants will bring the overnight urine to 
clinic, return unused pill s, undergo specimen collection for the collect ion of buccal cells, nasal brushing and blood . 
Participants will also be assessed for AEs, concomitant medications, compliance, and follow -up tobacco/alcohol 
assessment. Additional blood samples will be collected for safety labs (CBC -diff and CMP). Those w ho miss the 
overnight urine collection prior to Visit 7 will be provided with additional Avmacol®  pills and be asked to take the pills 
the evening of Visit 7 and collect overnight urine the night of the visit and return the urine to the clinic the followi ng day.  
 
After completion of Intervention Period 2, p articipants will be provided with information on how to contact the Arizona 
Smokers’ Helpline (toll free telephone number and URL to access the ASHLine website), which provides comprehensive 
services for  tobacco cessation.  
 
Participants will be contacted by telephone (or email) 10 -14 days after completing Intervention Period 2 for a final AE 
assessme nt and be reminded to return the AE Diary to the study office.  
 
4. PARTICIPANT SELECTIO N 
 
4.1 Inclusion Criteria  
 
4.1.1  Male or female current tobacco smokers  with ≥ 20 pack year s of self -reported smoking  exposure  and a current 
average use of ≥ 10 cigarettes/day . 
 
4.1.2  Age ≥18 years .  
 
4.1.3 Karnofsky  performance scale ≥ 70% (see Appendix A) . 
 
4.1.4  Participants must have normal organ and marrow function as defined below:  
Leukocytes   ≥3,000/microliter  
Absolute neutrophil count  ≥1,500/microliter  
Platelets   ≥100,000/microliter  
Total bilirubin   ≤ 2 × institutional upper limit of normal ( ULN )  
AST (SGOT)/ALT (SGPT)  ≤ 1.5 × ULN  
Creatinine   ≤ ULN  
 
4.1.5 Fertile subjects must use adequate contraception (abstinence, barrier methods, or birth control pills) prior to study 
entry and for the duration of study participation.  The effects of Avmacol®  on the developing human fetus are 
unknown. For this reason women of child -bearing potential and men must agree to use adequate contraception 
(hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  partic ipation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she 
should inform her study physician immediately.     
 
4.1.6   Ability to understand and the willingness to sign a written informed consent document.  
 
4.2 Exclusion Criteria  
 
4.2.1  History of invasive cancer within the past 2 years, with the exception of excised and cured non -melanoma skin 
cancer or  carcinoma in situ of the cervix.  
 
4.2.2  Chronic, current or recent (within the past 2 weeks ) use of systemic steroid doses equivalent to prednisone > 5 mg 
daily  for continued use > 14 days . Use of inhaled steroids, nasal sprays, and topical creams for small body areas is 
allowed.  
4.2.3  Participants may not be receiving any other investigational agents.  
  
4.2.4  History of allergic reactions attributed to compounds of similar chemical or biologic composition to Avmacol® . 
 
4.2.5  Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic 
congestive heart failure, unstabl e angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that 
would limit compliance with study requirements.  
 
4.2.6  Pregnant or lactating women.  
 
4.3 Inclusion of Women and Minorities  
 
Both men and women (as applicable) and members of all races and ethnic groups are eligible for this trial.  
 
4.4 Recruitment and Retention Plan  
 
Study participants will be recruited from the greater Tucson and Phoenix areas by word -of-mouth ; advertisement in local 
newspapers ; posting/distributing study information  around campus , through accessible listservs , and in community 
gathering places ; engaging collaborating clinics ; and through  use of the local Craigsl ist and social media . Study perso nnel 
will promote retention/adherence with regular contact with study subjects. The study team is committed to provide a 
friendly and comfortable study setting for participants from initial contact through the completion of their activities. 
Wherever possi ble, flexibility will be built into the study schedule to promote compliance . Recruitment and retention 
efforts will be evaluated routinely by the study personnel and modified as necessary to promote rapid accrual and to 
assure high retention of participan ts.   
 
5. AGENT ADMINISTRAT ION  
 
Intervention will be administered on an outpatient basis . Reported AEs and potential risks are described in Section 6.2.  
 
5.1 Dose Regimen and Dose Groups  
 
• The study agent is Avmacol®  
• Participants will be randomly assigned to one of two treatment arms:  
o High -Low Arm:  8 tablets Avmacol® per day during Intervention Period 1 and 4 tablets Avmacol® per 
day during Intervention Period 2  
o Low-High Arm:  4 tablets Avmacol® per day during Intervention Period 1 and 8 tablets Avmacol® per 
day during Intervention Period 2  
• Each Intervention Period is 10 -14 days.  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016   
5.2 Avmacol®  Administration  
 
• Participants will receive a supply of Avmacol® for each Interventi on Period upon confirmation  of overnight 
baseline urine collection .  
• Participants will be instructed to take the assigned Avamacol pills (4 or 8) with the evening meal . 
 
5.3 Run-in Procedures   
Not applicable . 
 
5.4 Contraindications  
 
Use of systemic steroid doses equivalent to prednisone > 5 mg daily is to be avoided during study participation.   
 
 
5.5 Concomitant Medications  
 
All medications (prescription and over -the-counter), vitamin and mineral supplements, and/or herbs taken by the 
partic ipant will be documented on the concomitant medication CRF and will include: 1) start and stop date, dose and route 
of administration, and indication. Medications taken for a procedure ( e.g., biopsy) should also be included.  
 
5.6 Dose Modification  
 
If a pa rticipant misses an Avmacol® dose, the dose is considered skipped and should not be replaced. If a participant 
vomits following an Avmacol® dose, the dose should not be retaken.   
 
If a participant experiences a Grade 1 AE, no dose modification will be made unless the AE is unacceptable to the 
physician or participant.  Doses may be held for unacceptable grade 1 AEs for up to 3 days.  If the AE has not resolved 
within the 3 days to a level acceptable by the participa nt or investigator , Avmacol® will be permanently withdrawn . 
 
For Grade 2 or Grade 3 AEs not related or unlikely to be related to study drug, the dose may be held for up to 3 days at the 
discretion of the investigator. If the AE has not resolved within the 3 days to a level acceptable by the participant or 
investigator, Avmacol® will be permanently withdrawn . 
 
If a participant experiences a Grade 2 AE possibly/probably/definitely attributable to Avmacol® , Avmacol®  may be held  
for up to 3 days until the AE is resolved to G rade 1 or less. If the AE is not resolved to Grade 1 or less within 3 days, 
Avmacol® will be permanently withdrawn and the participant followed for resolution of AEs. When possible and 
appropriate, participants withdrawn early  will be encouraged to return for sample collection and clinical labs for safety.  
 
Grade 3 events possibly/probably/definitely attributable to Avmacol® , and Grade 4 events regardless of relationship to 
study agent, will result in permanent withdrawal of s tudy agent. Participants will be followed for resolution of AEs. When 
possible and appropriate, participants withdrawn early will be encouraged to return for sample collection and clinical labs 
for safety.  
 
5.7 Adherence/Compliance  
 
5.7.1  Participants will be considered compliant for statistical analysis if they have taken  80% of their assigned study 
doses based on count of return  pills. 
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  5.7.2  The primary measure of compliance includes pill count.  The secondary measure of compliance wil l be the Intake 
Calendar.  Urinary  levels of sulforaphane  and its metabolites  can also be used to confirm compliance.  
 
6. PHARMACEUTICAL INFOR MATION  
 
6.1 Avmacol®  (IND information pending)  
Avmacol®  is a commercially available dietary supplement that conta ins glucoraphanin  (GR) plus the fully active enzyme 
myrosinase, thus yielding a higher and more consistent dose of sulforaphane  (SF) upon ingestion. Avmacol® tablets 
contain only GR -rich broccoli seed extract, freeze -dried broccoli sprouts for the myrosinase source, and the inert 
excipients required to form a tablet. Avmacol® is manufactured by Nutramax Laboratories, Inc., has been sold as a 
nutritional supplem ent in the United States since 2013, and is manufactured under GMP standards. The coated tablets 
contain 12.5 mg of GR, and have a minimum shelf life of 30 months at ambient temperature.  
 
6.2 Reported Adverse Events and Potential Risks  
 
Broccoli seed prep arations (BSP) have been studied extensively in more than 500 healthy volunteers in multiple Phase I 
and Phase II clinical trials without Grade 2 or higher adverse effects. Broccoli seeds contain high concentrations of 
glucoraphanin (GR), the glucosinolate  precursor of sulforaphane (SF), which is converted to SF by the release of intrinsic 
seed myrosinase during chewing or by thioglucosidaes in the microbiota in the human gut (40, 50, 51) . The isothiocyanate 
SF (1 -isothiocyanato -4R-(methylsulfinyl)butane) was originally isolated from commercial broccoli, and is one of the most 
potent naturally -occu rring inducers of cytoprotective enzymes identified to date (52). SF activates the KEAP1 -NRF2 
signaling pathway, thereby increasing transcription of antioxidative and detoxication genes. For example, SF has been 
shown to induce cytoprotective enzymes in a variety of animal and human cell lines and tissues, including rat  and human 
mammary and prostate cell lines  (45). 
 
In our initial clinical trials, we investigated BSP in the form of re -hydrated, previously lyophilized broccoli sprout 
powders rich in either GR or SF produced by the Cullman Chemoprotection Center at Johns Hopkins under the 
supervision of Drs. Jed Fahey and Paul Talalay.  Broccoli sprouts (Brassica oleracea) were grown from specially selected 
BroccoSprouts™ seeds to provide a consistent yield of glucoraphanin or  sulforaphane. In our initial trial, the GR -rich 
powder was considered as a food by the Johns Hopkins IRB. It is simply the freeze -dried powder derived from a hot water 
extract of broccoli sprouts. In 2010, the US FDA made a determination that beverages co ntaining SF -rich broccoli sprout 
powders (but not GR -rich broccoli sprout powders) must be considered as drugs because the SF is formed ex vivo from 
the plant by the addition of myrosinase -containing daikon seeds during the preparation of the SF -rich powde r. Thus, 
subsequent trials in Qidong, China as well as our pilot study at the University of Pittsburgh (NCT 02023931, “Broccoli 
Sprout Extracts in Healthy Volunteers: A Pilot Study of NRF2 Pathway Activation in Oral Mucosa”) have been conducted 
with an IND  from the FDA (#112038 “Broccoli Sprout Extract for Protection Against Environmental Toxins”) held by 
Thomas Kensler , PhD.   
 
There are three main problems in achieving consistent delivery and bioavailability of active SF by means of lyophilized 
broccoli s prout extracts: (1) SF is only moderately storage - and heat -stable over time, especially in aqueous solution.  (2) 
SF-rich broccoli sprout extract powders are extremely hygroscopic and the preparation of capsules containing accurate 
doses by weight is chal lenging and very expensive. (3) Administration of GR as an oral precursor of SF results in highly 
variable conversions of GR to SF metabolites (dithiocarbamates) among individuals, ranging from 1 – 40%, but fairly  
consistent between individuals. Oral deliv ery of SF -rich broccoli sprout extract, on the other hand, results in consistent 
conversion of 60 -80% of it to urinary dithiocarbamate metabolites.  
 
In this clinical study, BSP will be provided in the form of the commercially available dietary supplement, Avmacol® . 
Although a number of dietary supplements containing GR have been available in the U.S. market for several years now, 
Avmacol®  is the first commercial product to contain GR plus the fully active enzyme myrosinase, thus yielding a higher 
and much m ore consistent SF dose upon ingestion. Avmacol® tablets contain only GR -rich broccoli seed extract, freeze -
dried broccoli sprouts for the myrosinase source, and the inert excipients required to form a tablet. They are manufactured 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  by Nutramax Laboratories,  Inc.  Avmacol® has been sold as a nutritional supplement in the United States since 2013, and 
is manufactured under GMP standards. The coated tablets contain 12.5 mg of glucoraphanin, which has a shelf life of at 
least 30 months at ambient temperature (on going stability testing). Based on previous human studies with both dietary and 
topical broccoli sprout extracts, and related broccoli seed preparations, and the absence of severe or serious risks (no 
Grade II toxicities have been observed in > 500 patient s), we do not anticipate serious AEs to be associated with the 
administration of Avmacol® to study participants in this proposed trial. Consistent with that expectation, in 2016 Bauman 
completed a healthy volunteer study (N=10) where Avmacol®  was dosed at 8 tablets daily for 3 days. No grade 2 or 
higher AEs were observed (Bauman, unpublished data).  
 
6.2.1   Non-clinical Toxicology  
 
A number of animal studies have investigated the biological effects and toxicology of oral SF -containing broccoli seeds 
and SF i tself. While these investigations have examined a wide variety of endpoints and effects, they have demonstrated 
the overall in vivo safety and beneficial biological effects of broccoli seeds and SF. Animal studies are summarized 
below.  
 
Myzak et al. treate d C57BL mice with 6 µmol   SF/Day for 10 weeks with no adverse effect on body weight, hematocrit, 
or spleen weight. Taking into account species scaling factors, human consumption of 106 g of broccoli seeds daily would 
achieve daily SF intake similar to this  murine study  (53). 
 
Jones et al. treated male F344 rats with SF 50 mg/kg/Day (280 µmol  /kg/Day) by gavage for five Days. The dose was 
selected based on reports of non -toxicity and efficacy in inducing cytoprotective enzymes in other model systems. During 
the study , 2 of 10 an imals in the SF treatment group died after feeding due to aspiration of the dose. On the sixth Day, 
after five Days of SF feeding, rats were sacrificed and organs examined. The SF was well tolerated by the animals and 
there was no apparent toxicity over th e duration of the study. The SF feeding did not affect the relative weights of the 
prostate, kidneys, liver or bladder. Body weight was not affected compared to control animals, though there was an 8% 
decrease in body weight in the SF treated group compare d to initial weight. The SF dose used in this study is >10 -times 
greater than that achieved by the proposed BSP dosing for our protocol (54). 
 
Zhang et al. treated female Sprague -Dawley rats with BSP to study the effect on tissue GST and NQO1 and the urinary 
excretion levels of isothiocyanate (ITC ) metabolites. These experiments included administration of BSP providing 40, 80, 
and 160 µmol   isothiocyanate/kg body weight daily for 14 Days. None of the extract doses were associated with any sign 
of toxicity, with all rats in good health and body weig ht gain not significantly different among treatment and control 
groups. No gross abnormalities were detected at necropsy. No pathological changes were visible in rat bladder tissues 
when examined microscopically. BSP in the doses administered effectively i nduced GST and NQO1 enzyme expression 
in rat bladder, duodenum, and stomach in a dose -dependent fashion. Significant enzyme expression was induced in rat 
colon, kidney, and lungs at the higher dose of broccoli seed extract. Measurement of urinary ITC and m etabolites by 
cyclocondensation assay showed extensive (70 -78%) elimination of the ITC doses within 24 hours. ITCs are known to be 
metabolized in vivo mainly through the mercapturic acid pathway and to be excreted in the urine  as NAC conjugates  (55). 
 
6.2.2 Mutagenicity  
 
In a study in rats by Yoxall et al. conversion of 2 -amino -3-methylimidazolo -[4,5-f] quinoline to mutagenic  intermediates 
(Ames test) was reduced by treatment with SF at both 3 and 12 mg/kg/Day (17 and 68 µmol   /kg/Day) doses  (56). 
 
6.2.3   Clinical S afety and Efficacy  
 
Cruciferous vegetables, including broccoli sprouts, are generally regarded as safe and are regular dietary comp onents in 
many regions of the world. Previous estimates of the daily dietary intake of cruciferous vegetables vary regionally, 
averaging 40 g/day in Singapore (57), 11 g/day in the United States (58), 16 g/day in Canada (59), 30 g/day in the UK 
(60), and 112 g/day in Japan (61).  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016   
Shapiro et al. conducted a double -blind, placebo controlled, randomized, Phase I study of two BSPs, beverages containing 
SF-rich or GR -rich powder made from sprouted broccoli seeds, in healthy indiv iduals to determine the safety and 
tolerance of repeated oral administration. Twelve healthy human volunteers received doses of BSP every 8 hours for 7 
Days (total 21 doses) while undergoing clinical evaluation and a battery of laboratory tests. Doses used  in 3 cohorts of 3 
subjects and 1 control were 25 µmol glucosinolates, 100 µmol glucosinolates, and 25 µmol isothiocyanates,  respectively. 
Thus subjects received 75  – 300 µmol glucosinolates daily, equivalent to 12 - 50 g of fresh broccoli seeds, or 75 µmo l 
isothiocyanate. No clinical AEs were reported. With regard to laboratory testing, samples were obtained 6 times during 
the 19 Day study and included evaluation of the blood for the following: CBC with differential, reticulocyte count, PT, 
PTT, BUN, creat inine, Na, K, CO2, Cl, glucose, albumin, direct/total bilirubin, alkaline phosphatase, AST, ALT, GGT, 
T3, T4, TSH. Urinalysis was performed for urine creatinine, and urine dithiocarbamates (DTC). Two of 12 individuals 
(both receiving active preparations) s howed an increase in plasma ALT exceeding the upper limit of normal with one 
meeting criteria for a Grade 1 toxicity. Notably, ALT levels rose for all subjects during the course of the study including 
placebo -treated subjects. Plasma AST levels rose above normal on Day 19 for 2 of 12 subjects. They were released from 
the inpatient portion of the study on Day 17 and their post -discharge activities (i.e., possible alcohol intake) could not be 
ascertained. Monitoring of TSH levels demonstrated that in 3 of 12 subjects (2 active treatment, 1 placebo), TSH levels 
exceeded the upper limit of normal during or after the dosing period. Notably, TSH levels rose for 11 of 12 subjects 
during the first 6 Days of hospitalization before broccoli seed administration was beg un. TSH increases were not 
associated with any clinical symptoms or abnormalities of T3 or T4. Evaluation by 2 independent endocrinologists 
determined that the changes in TSH were mild and reversible and did not pose an obstacle to further studies with 
administration of BSPs. No other significant laboratory abnormalities occurred. Thus, this Phase I safety study in healthy 
volunteers revealed no evidence of systematic, clinically significant adverse effects that could be attributed to the 
administration of repeated doses of broccoli sprout extracts containing SF or GR (41). 
 
Cornblatt et al. conducted a study to assess the bioavailability of SF -rich broccoli sprout extract in human breast tissue. In 
this proof -of-principle study, 8 women undergoing elective mammoplasty consumed a preparation containing 200 µmol 
of SF approxima tely 50 minutes prior to surgery. The extract was well -tolerated without any AEs or complications. SF 
metabolite levels measured by cyclocondensation reaction as dithiocarbamates were used to determine SF distribution. 
Mean post -dose plasma dithiocarbamate  (DTC) level was 0.92 ± 0.72 µM, and mean epithelial/stromal enriched breast 
tissue DTC concentration was 1.45 ± 1.12 and 2.00 ± 1.95 picomol/mg tissue for right and left breast respectively. In 
addition, the investigators were able to measure  NQO1 and HO -1 transcripts in the human breast tissue, demonstrating the 
feasibility of assessing a pharmacodynamic action of SF in these tissues (45). 
 
In an ongoing randomized clinical trial at Johns Hopkins, 21 women completed a 10 day intervention of broccoli sprout 
extract or placebo (mango juice). There were only three grade 1 mild gastrointestinal AEs reported and no significant 
changes (1.5 times o r greater) in bloods (comprehensive metabolic panel, full blood count, coagulation panel and thyroid 
tests), taken pre and post intervention (personal communication K. Visvanathan).  
 
In the cross over trial conducted by Egner et al (36), 2 of the fifty participants randomized to receive the SR -rich beverage 
(150 µmol/day) during either the first or second wave complained of nausea or bitter taste and dropped out of the study. 
Serum chemistry studies conducted on samples obtained after the last of seven daily doses of SF did not  present any 
abnormal values. This study suggests that 150 µmol SF/day, approximates the maximum tolerated dose.  
 
A number of small pilot clinical studies have evaluated the effect of broccoli sprouts on antioxidant endpoints:   
 
Murashima and colleagues r eported in 2004 on the elevation of multiple biomarkers of oxidative stress following a one -
week course (6 young male and 6 young female smokers) of 100 g/d of fresh broccoli sprouts  (62). Plasma markers were 
measured before and after treatment. Treatment produ ced decreases in serum total cholesterol, LDL cholesterol, 
coenzyme Q10, plasma cystine and phosphatidylcholine hydroperoxide, and urinary 8 -isoprostane, and 8 -OHdG. 
Increases in CoQ10H2/CoQ10 ratio, and HDL cholesterol were observed.  Blood lymphocyte mar kers, natural killer cell 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  activity, triacylglycerol, urea nitrogen, uric acid, AST, ALT, γ -GPT, and plasma amino acids were also measured and 
there were no before - to after -treatment differences in any of these biomarkers.  
 
In 2009, a group at UCLA reporte d on the ability of orally administered broccoli sprout homogenates (BSH) to increase 
phase 2 antioxidant enzymes in the upper airway (63). After feeding 57 subjects doses of BSH ranging from 25 to 200 g 
on 3 separate days, followed on the 4th day by blood a nd nasal lavage collection, there was a dramatic and dose -
depe ndent increase in phase 2 enzyme expression (mRNA for GSTM1, GSTP1, HO -1, and NQO1). Induction of 
individual phase 2 enzymes in nasal lavage cells was strongly correlated. No serious AEs were re ported, and dose 
intolerance or side effects of broccoli sprouts were not observed, and mild, digestive effects are presented in the report.   
 
Christiansen et al (Denmark) report that ingestion of broccoli sprouts does not improve endothelial function in human 
beings with hypertension (n = 40 hypertensive, non -diabetic subjects with ch olesterol in the normal range) (64). Subjects 
were fed 10 g of dried broccoli sprouts for 4 weeks, and their blood pressure, endothelial function (measured by flow -
mediated dilation), and blood samples were obtained every other week. Glucoraphanin content of the sprouts was 
measured, and equ ated to a dose of 259 µmol GR/d – a reasonable level, but in light of our findings perhaps not high 
enough to expect a measurable effect due to low conversion of GR to SF by the intestinal microflora of individuals.  
 
A recent report from Iran, describes th e effect of oral broccoli sprouts on a variety of oxidative stress biomarkers in a 
double -blind, placebo -controlled, randomized controlled trial, in type 2 diabetes patients.  Eighty -one patients were 
randomly assigned to one of three treatment groups for 4 weeks. They received either 10 g/d, or 5 g/d broccoli sprout 
powder (BSP), or a placebo of cornstarch and chlorophyll  (65). The authors report that consumption of BSP resulted in a 
significant decrease in malondialdehyde, oxidized LDL cholesterol, and “oxidative stress index”, and a significant 
increase in total serum antioxidant capacity. They found no significant effect on “total antioxidant status” or fasting blood  
glucose.  Since this study employed an over -the-counter broccoli sprout supplement and the authors did not make 
independent determ inations of its SF content, and since the fasting blood glucose values for the three groups were not 
closely matched, there is substantial concern about the robustness of reported results, although there do appear to be clear 
trends for difference.  
 
In a r ecent phase II study of men wi th recurrent Prostate Cancer at  the Knight Cancer Institute in Portland Oregon, 
treatment with 200 µmol of sulforaphane per day for 20 weeks produced no major side effects and AEs were mostly grade 
1 gastrointestinal (66). 
 
Another intervention was conducted October 2011 to January 2012, in which 267 healthy volunteers in Qidong Province, 
China (a region with extremely high liver c ancer prevalence) received 84 consecutive daily doses of a broccoli sprout 
beverage containing 600 µmol of glucoraphanin and 40 µmol of sulforaphane, or an indistinguishable placebo (38). The 
study participants comprised 136 treated with broccoli sprout beverage and 131 placebo controls. Of the 267 participants 
completing the study, 50% consumed all assigned doses, and the remaining participants consumed at least 80 of the 84 
doses. Extensiv e blood chemistries at the termination of the study showed that the means of 13 analytes were identical 
between treated and control groups, and that specifically no abnormalities were detected in BUN, creatinine, and 
transaminases (ALT and AST). Three indi viduals, 2 in the placebo arm and 1 in the treated arm, had slightly elevated total 
bilirubin (1.1, 1.6, 1.8 mg/dL) and two individuals, 1 each in placebo and treated arms, had slightly elevated direct 
bilirubin (0.5, 0.6 mg/dL levels).  
 
In summary , no gr ade 2 or higher AEs have been observed in multiple phase I and II clinical trials evaluating broccoli 
seed preparations in more than 500 participants. Reported grade I AEs have included : the poor taste of the study agent , 
most common during ingestion of SF -rich broccoli sprout extract beverages, eructation, and flatulence. During the healthy 
volunteer study with Avmacol® , the taste of the study agent was not a source of toxicity – likely because the taste is 
masked by encapsulation.  
 
 
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  6.3  Availability  
 
Avmacol® is a commercially available dietary supplement manufactured under GMP conditions by Nutramax, and will be 
provided to investigators at the University of Arizona without cost. Avmacol®  will be shipped in bottles containing 500 
tablets, and will be repackaged by the University of Arizona Investigational Drug Pharmacy.  A total of 16,000 tablets ( 32 
bottles of #500) from the same lot number will be shipped.  
 
6.4 Agent Distribution  
 
Nutramax will ship Avmacol® at ambient temperature to the Investigational Drug Pharmacy at the address below:  
 
Jennifer Hoiles, PharmD  
Investigational Drug Pharmacy  
Room 0626 (basement)  
Banner - University Medical Center Tucson  
1501 N. Campbell Ave.  
Tucson, Arizona  85724  
 
The IDP will repackage Avmacol®  into ind ividually dispensed bottles of 84 tablets, which will then be delivered to the 
UACC Chemoprevention Clinic. Bottle s will be dispensed from the Chemoprevention Clinic according to the Intervention 
Treatment Period (two bottles for the high dose treatment pe riod; one bottle for the low dose treatment period).  
 
 
 
 
6.5  Agent Accountability  
 
The Investigator, or a responsible party designated by the Investigator, must maintain a careful record of the inventory and 
disposition of all agents received from DCP using the NCI Drug Accountability Record Form (DARF). The Investigator is 
required to maintain adequate records of receipt, dispensing and final disposition of study agent. This responsibility has 
been delegated to  UAZ Consortium staff. Include  on receipt record from whom the agent was received and to whom study 
agent was shipped, date, quantity and batch or lot number. On dispensing record, note quantities and dates study agent 
was dispensed to and returned by each participant.  
 
6.6 Packaging and Label ing 
 
Avmacol®  bottles will packaged in bottles of 84 tablets and will be labeled by the IDP, The label will contain, but not be 
limit ed to, the following information:  
• Protocol number  
• Patient study ID number (blank, to be filled in at dispensal)  
• Dosing information (take 4 tablets every evening; OR take 8 tablets every evening)  
• Expiration date (provided as testing due date, as stability testing is ongoing and 36 month data will be provided 
during the course of the study)  
• Number of tablets per contain er 
 
6.7 Storage  
 
Study agents  will be stored in a secure investigational agent storage room in the UACC Chemoprevention  Clinic  at 
temperatures between 15 C and 30C (59F and 86F). 
 
6.8 Registration/Randomization  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016   
Participants will be considered registered on the date they sign the approved informed consent document with a member 
of the study staff.  The study coordinator will contact the UAZ Consortium Office for a subject number when the subject 
has been consented.  See section 13.2 for details of the study randomization procedures.  
 
6.9 Blinding and Unblinding Methods  
 
Not applicable.  
 
6.10 Agent Destruction/Disposal  
 
All unused study agents will be disposed according to the institutional standards.  Per the University of Arizona Cancer 
Center ph armacy’s investigational drug destruction policy, returned study agents and de -identified returned drug 
containers are disposed of in a chemo -safety biohazard waste container.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  7.2 Screening  Evaluation  
 
Potential participants will undergo a brief interview to determine initial eligibilit y. During this interview, potential 
participants will be queried on the inclusion/exclusion criteria that could be addressed by phone  such as smoking history, 
age, and general state of health.  The study procedures and risks will be reviewed. Those who are  intere sted in 
participating in the study and have been determined initially  eligible will be scheduled for a clinic visit.   
 
At the initial clinic visit  (Visit 1, Screening Visit) , the IRB -approved consent form will be reviewed with each potential 
study s ubject. All participants will be required to read and sign the consent form prior to enrollment. Once informed 
consent is obtained from provisionally eligible participants, they will be entered into the study and subjected to the 
following procedures:   
• Height, weight, blood pressure, pulse, temperature measurements  
• A brief physical exam consisting of an examination of the heart, lungs and abdomen  
• Karnofsky  performance status assessment  
• Evaluation of concurrent medication and supplement use, tobac co use history, medical history  
• Baseline tobacco/alcohol use assessment   
• Collection of blood for clinical labs  (complete blood count with differential (CBC -diff), comprehensive metabolic 
panel (CMP)  
• Women of childbearing capacity wi ll have a urine pregnancy test  
• Participants provided with a daily diary for recording any AEs and medication usag e 
• Participants provided with a urine collection kit (an overnight urine collection container, a collection hat, and 
instructions for collecting overnight urine) to be used th e night before Visit 2  
  
 Once determined eligible, participants will be randomized (1:1) to one of the following arms: High -Low Arm (8 tablets 
Avmacol® per day during Intervention Period 1 and 4 tablets Avmacol® per day during Intervention Period 2) and Low -
High Arm (4 tablets Avmacol® per day during Intervention Period 1 and 8 tablets Avmacol® per day during Intervention 
Period 2).   
 
7.3 Evaluation During Study Intervention  
 
Participants will return to the clinic for Baseline Specimen Collec tion for Intervention Period 1  (Visit 2). Participants will 
be contacted prior to the visit to remind them to collect overnight urine the night prior to Visit 2. Participants will bring  
the overnight urine ( for urinary tobacco carcinogens , systemic study a gent exposure , and bio-measurement of tobacco 
exposure ) to the clinic and undergo the following procedures:  
• Collection of buccal cells ( for NRF  target gene transcripts  and nuclear morphometry ) 
• Collection of nasal brushing (banked for gene expression analysis)  
• Collection of  blood for research (for genotyping and banking)  
• Assess ment  of AEs, concomitant medications, and current tobacco use  
• Urine pregnancy test , if applicable  
• Participants provided with Avmacol® pills for Intervention Period 1 after confirmation of overnight urine 
collection.  
• Participants provided with an Intake Cale ndar for recording agent intake  
Those who miss the overnight urine collection prior to this visit will be asked to collect overnight urine the night of the 
visit and  return the urine to the clinic  the following day .  
 
During Intervention Period 1 (10 -14 days), participants in the High -Low Arm will take 8 tablets of Avmacol® each day 
and participants in the Low -High Arm will ta ke 4 tablets of Avmacol® each day. Participants will be instructed to take the 
Avmacol®  pills with the evening meal. Day 1 of the Intervention Period 1 begins the day the first dose is taken.  
 
During Intervention Period 1, participants will return to the clinic on Day 4 , 5, 6, 7 or 8  for an Interim Visit (Visit 3) to 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  undergo the following procedures:  
• Collection of buccal cells  
• Assess ment  of AEs, concomitant medications and current tobacco use  
• Participants provided with a urine collection kit to be used th e night before Visit 4. 
 
Participants will return to the clinic at the end of Intervention Period 1 (Visit 4) . Participants will be contacted prior to the 
visit to remind them to collect overnight urine the night prior to Visit 4. Participants will bring the overnight urine to the 
clinic and undergo the following procedures:  
• Return unused pill s and Intake Calendar   
• Collection of buccal cells  
• Collection of  nasal brushing  
• Collection of blood for research  
• Assess ment  of AEs, concomitant medications, compliance , and current tobacco use  
• Participants provided with a urine collection kit to be used the night before Visit 5 
Those who miss the overnight urine collection prior to this visit will be provided with additional study pills and be asked 
to take the study pills in the evening of Visit 4 and collect overnight urine the night of the visit and return the urine to the 
clinic  the following day .  
 
Participants will undergo a Washout Period (10 -14 days) after completing Intervention Period 1. After the Washout 
Period, participants will return to the clinic (Visit 5) . Participants will be contacted prior to the visit to remind them to 
collect overnight urine the night prior to Visit 5. Participants will bring the overnight urine to the clinic and undergo the  
followi ng procedures:  
• Collection of buccal cells  
• Collection of nasal brushing  
• Collection of blood for research  
• Assess ment  of AEs, concomitant medications, and current tobacco use   
• Urine pregnancy test, if applicable   
• Participants provided with Avmacol® pills for Intervention Period 2 after confirmation of overnight urine 
collection.  
• Participants provided with an Intake Cale ndar for recording agent intake   
Those who miss the overnight urine collection prior to this visit will be asked to collect overnigh t urine the night of the 
visit and  return the urine to the clinic  the following day .  
 
During Intervention Period 2 (10 -14 days), participants in the High -Low Arm will take 4 tablets of Avmacol ® each  day 
and participants in the Low -High Arm will take 8 tab lets of Avmacol ® each  day. Participants will be instructed to take the 
Avmacol®  pills with the evening meal.  Participants will be provided with an Intake Calendar for recording agent intake.  
Day 1 of the Intervention Period 2 begins the day the first dose  is taken.  
 
During Intervention Period 2, participants will return to the clinic on Day 4 , 5, 6, 7 or 8 for an Interim Visit (Visit 6 ) to 
undergo the following procedures:  
• Collection of buccal cells  
• Assess ment  of AEs, concomitant medications and current tobacco use  
• Participants provided with a urine collection kit to be used the night before Visit 7. 
 
Participants will return to the clinic at the end of Intervention Period 2 (Visit 7) . Participants will be contacted prior to the 
visit to remind them to co llect overnight urine the night prior to Visit 7. Participants will bring the overnight urine to the 
clinic and undergo the following procedures:  
• Return unused pill s and Intake Calendar   
• Collection of buccal cells  
• Collection of nasal brushing  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  • Collection of blood for research and for safety labs (CBC -diff and CMP)  
• Assess ment  of AEs, concomitant medications, compliance, and current tobacco use  
• Follow -up tobacco/alcohol  use assessment  
Those who miss the overnight urine collection prior to this vis it will be provided with additional study pills and be asked 
to take the study pills in the evening of Visit 7 and collect overnight urine the night of the visit and return the urine to the 
clinic.  
 
7.4 Evaluation at Completion of Study Intervention  
 
See section 7.3 for evaluation at the end of intervention for each Intervention Period . In addition, p articipants will be 
provided with information on how to contact the Arizona Smokers’ Helpline (toll free telephone number and URL to 
access the ASHLine websit e), which provides comprehensive services for tobacco cessation.  
 
7.5 Post-intervention Follow -up Period  
 
Participants will be contacted by telephone (or email) 10 -14 days after completing Intervention Period 2 for a final AE 
assessment and will be reminde d to return the AE Diary to the study office  using a stamped, addressed envelope provided 
by the study office . 
 
7.6 Methods for Clinical Procedures  
 
Buccal cell collection : Participants will be instructed to rinse their mouths with plain water  for approximately 10 seconds 
prior to collection . Buccal (inner cheek) cells wi ll be collected with 4 buccal cytobrush es per collection  (2 on the right, 2 
on the left) . The first cytobrush will be vigorously brushed across the buccal surface of the select ed side for a total of 10 
strokes, approximately 15 seconds, taking care to cover the entire surface area. Upon completion, the cytobrush will be 
immediately swirled into a cryovial with RNALater to deposit the cells  then discarded . The same process  will b e repeated 
with a second cytobrush on the same inner cheek.  A third cytobrush will then be used to collect cells from the o pposite 
buccal surface , and swirled into the same cryovial . At the completion of the first three buccal cell collections , the cryovi al 
will contain the buccal cells deposited from a total of 3 brushes. The cryovial will be frozen for later gene expression 
analysis. A fourth and final cytobrush will be used to collect cells from the most recently collected buccal surface (the sid e 
that has only been collected once). This  fourth brush will be rolled across the length of three glass slides , then fixed for 
nuclear morphometry .  
 
Nasal epithelium collection : A nasal speculum will be used to spread one of the nare s while a standard cytology brush 
will be inserted underneath the inferior nasal turbinate. The brush will be rotated in place for 3 s econds , removed, and 
immediately placed in 1 ml of RNAProtect Cell solution. The same nare will be brushed again with a nother cytology 
brush as described above  and immediately placed in RNAProtect Cell solution .  
 
 
8.  CRITERIA FOR EVA LUATION AND ENDPOINT  DEFINITION  
 
8.1 Primary Endpoint  
 
The primary endpoint is to determine the change (from baseline to end -of-intervention for each Intervention Period) in the 
urinary excretion of the mercapturic  acid of benzene after Avmacol® intervention. The urinary levels of mercapturic  acid 
of benzene will be normalized by urinary creatinine levels t o account for varying water content of individual urine 
samples. The normalized mercapturic  acid of benzene at end -of-intervention will be compared with that at baseline. The 
changes following 4 tablets of Avmacol® per day and after 8 tablets of Avmacol® per day will be determin ed separately.  
 
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  8.2 Secondary Endpoints  
 
The secondary endpoints are:  
• To determine the changes  (from baseline to end -of-intervention for each Intervention Period) in the 
urinary excretion of the mercapturic  acids of acrolein and crotonaldehyde after Avmacol®  intervention. 
Similarly, the urinary biomarkers will be normalized by the urinary creatinine levels. The changes 
following 4 tablets of Avmacol® per day and after 8 tablets of Avmacol® per day will be calculated 
separately for each tobacco carcinogen.  
• To determine whether Avmacol®  increases the urinary excretion o f the mercapturic acids of tobacco 
carcinogens , normalized by bio-measurement of tobacco exposure. Bio-measurement o f tobacco expo sure 
will be  assessed by the total urinary levels of nicotine and major nicotine metabolites  (i.e., the sum of the 
molar concentrations of nicotine and major nicotine metabolites in urine) . The changes following 4 tablets 
of Avmacol® per day and after 8 ta blets of Avmacol® per day will be calculated separately for each 
tobacco carcinogen.  
• To determine the changes (from baseline to day 4 -8 and to end -of-intervention) in the NRF2 target gene 
transcripts, assessed by the expression of NQO1 , in the buccal cells  after Avmacol® intervention. The 
changes following 4 tablets of Avmacol® per day and after 8 tablets of Avmacol® per day will be 
determined  separately . 
• To determine whether there is a dose -response relationship between  the Avmacol®  dose and the 
detoxi fication of tobacco carcinogens and the change in the  NRF2 target gene transcripts . 
• To determine the relationship between systemic study agent exposure, assessed by the total urinary levels 
of sulforaphane and its glutathione -derived metabolites  (i.e., the s um of the molar concentrations of 
sulforaphane and its glutathione -derived metabolites in urine) , and changes in detoxification of tobacco 
carcinogens and NRF2 target gene transcripts.   
  
 
The study also includes the following explorative endpoints:  
• To determine whether the GSTM1  and GSTT1  genotypes are important genetic modulators of 
detoxi fication of tobacco carcinogens . The change in the urinary excretion of the mercaptoruinc acids of 
tobacco carcinogens will be compared between GSTM1 -null and GSTM1 -positive subjects and between 
GSTT1 -null and GSTT1 -positive subjects.  
• To bank specimens for future research including tobacco gene signature in nasal brushing , and fixed 
buccal cells for nuclear morphometry . 
 
 
8.3 Off-Agent Criteria  
 
Participants may stop taking study agent for the following reasons: completed the protocol -prescribed intervention, AE or 
serious adverse event  (SAE) , inadequate agent supply, noncompliance, concomitant medica tions, medical 
contraindication . Participants w ill continue to be followed, if possible, for safety reasons and in order to collect endpoint 
data according to the schedule of events.   
 
8.4 Off-Study Criteria  
 
Participants may go ‘off -study’ for the following reasons: the protocol intervention and any protocol -required follow -up 
period is completed, AE/SAE , lost to follow -up, non -compliance, concomitant medication, medical contraindication, 
withdraw consent, dea th, determination of ineligibility (including screen fa ilure), pregnancy .  
 
 
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  8.5 Study Termination  
 
NCI, DCP as the study sponsor has the right to discontinue the study at any time.  
 
9. CORRELATIVE/SPECIAL STUDIES  
 
9.1 Rationale for Methodology Selection  
 
Urinary metabolites of the tobacco carcinogens, including benzene, acrolein and crotonaldehyde will be quantified by 
liquid chromatography tandem mass spectrometry (LC -MS/MS), as previously described by Hecht and colleagues (67, 
68). This method is sensitive and speci fic for quantification of the urinary levels of these tobacco carcinogens.  
 
Urinary levels of sulforaphane and its metabolites will be quantified by liquid chromatography tandem mass spectrometry 
(LC-MS/MS), as previously described (69). This method is sensitive and specific for quantification of the urinary levels of 
sulforaphane and its metabolites.  
 
Urinary levels of nicotine and its major metabolites  will be quantified by liquid chromatography tandem mass 
spectrometry (LC -MS/MS), as previously described (70). This method is sensitive and specific for quantification of the 
urinary levels of nicotine and its major metabolit es. 
 
Buccal cell NRF2 target gene transcripts will be determined using quantitative real -time PCR as previously described 
(39). 
 
GSTM1  and GSTT1  will be genotyped using standard methods as previously d escribed (71). 
 
Nuclear morphometry, a quantitative mathematical characterization of the spatial and statistical distribution of nuclear 
chromatin across the spectrum o f transformation, will be conducted according to methods previously described (72, 73) . 
 
9.2 Comparable Methods  
 
The methods proposed are standard methodologies used in other research studies. The resulting data will be able to be 
compared to existing data.  
 
10. SPECIMEN MANAGEM ENT  
 
10.1 Laboratories  
 
Clinical chemistry and hematology panels will be outsourced to a contracted commercial diagnostic laboratory service 
(i.e., Sonora Quest). If urine is collected for a cotinine leve l at the screening visit, it will also be outsourced to Sonora 
Quest laboratory.   
 
The urinary biomarker analysis will be conducted in the University of Arizona Cancer Center Analytical Chemistry 
Shared Resource directed by Dr. Sherry Chow.   
 
The N RF2 target gene transcripts and GSTM1/P 1 genotying will be performed at a University of Arizona research 
laboratory under the supervision  of Dr. Donna Zhang.  
 
The nuclear morphometry will be performed in the University of Arizona Cancer Center Karyometry Labo ratory directed 
by Dr. David Alberts under the supervision of Dr. Julie Bauman.  
  
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  10.2 Collection and Handling Procedures  
  
Blood for clinical chemistry, hematology and coagulation panels  
Twelve and a half  milliliters of blood (1 x 8.5 ml SST tube; 1 x 4 ml Lavender -EDTA tube) will be collected at screening 
and at the end of intervention for CBC with diff and CMP. The SST tube will be held at room temperature for 30 min and 
then centrifu ged. The lavender EDTA  tube will be gently inverted to mix for anticoagulation.  Blood tubes will be 
prepped, labeled, and packaged according to the recommendation from the diagnostic lab oratory .  All samples will be 
refrigerated prior to transfer to the commercial laboratory and sent for immediate analysis.  
 
Urine for pregnancy test  
A single void urine will be collected and tested for pregnancy in the clinic according to package instructions.  
 
Overnight urine collection  
Overnight urine will be  collected the night prior to Visits 2, 4 , 5, 7 . Participants will record the start and stop time of urine 
collection on a designated collection form  and will bring overnight urine collections to research visits. If urine collection 
was not done  the night prior to the visit, overnight urine may b e collected the night of the visit . The volume of urine 
collected from each overnight void will be recorded by study staff to the nearest 10 mL .  Five 5 mL aliquots of urine will 
be retained for testing and the remaining urine discarded. The sample tubes w ill be labeled with the study ID, participant 
ID, and visit number/date and stored at -70 or below until analysis.  
 
Buccal cell collection  
Buccal cells  will be collected at Visits 2, 3, 4, 5, 6, 7 . As described, the buccal cells will be collected in two forms: 1) into 
a cryovial preserved in  RNALater  upon collection  (the first 3 brushes); 2) fixed onto 3 glass slides for nuclear 
morphometry (the fourth brush) . Cryovial s pecimens will be labeled wit h the study ID, participant ID, and visit 
number/date  and stored at -70 or below until analysis.  Buccal cell glass slides will also be labeled with the study ID, 
participant ID, and visit number/date. After the buccal cell glass slides are collected, t he slides are allowed to dry at room 
temperature for about 30 minutes. Buccal cell slides are then fixed for 10 minutes in room temperature 10 % neutral 
buffered formalin (using  a coplin jar).  Slides can then be dried for as long as overnight at room temperatu re in a slide 
rack.  Slides will then be stored in a labeled slide box stored at room temperature.  
 
Blood for genotyping and banking  
Twelve and a half  milliliters of blood (1 x 8.5 ml SST tube; 1 x 4 ml Lavender EDTA tube) will be collected at Visit 2. 
SST tube will be held at room temperature for 30 min followed by centrifugation. Serum will be aliquoted evenly into 5 x 
2 ml cryovials. The l avender -EDTA tube will be inverted gently 5 times  and the wh ole blood will be aliquoted evenly into 
4 x 2 ml cryovials . Cryovials will be labeled with the study ID, participant ID, and visit number/date and stored at -70 or 
below until analysis.  
 
Eight and a half milliliters of blood (1 x 8.5 ml SST tube) will be collected at Visit s 4, 5, 7 . SST tube will be held at room 
temperature for 30 min followed by centrifugation. Serum will be aliquoted evenly into 4 x 2 ml cryovials. Cryovials will 
be labeled with the study ID, participant ID, and v isit number/date  and sto red at -70 or below until analysis  
 
Nasal epithelium brushi ngs 
Nasal epithelium brushing samples will be collected at Visits 2, 4, 5, 7. All nasal brushing samples will be preserved in 
RNAprotect Cell Reagent (Qiagen) upon collection and stored at  -70 or below . Specimens will be labeled with the study 
ID, participant ID, and visit number/date  and stored at -70 or below until analysis.  
 
 
10.3 Shipping Instructions  
 
Collected frozen specimens will be placed on ice packs  and hand delivered to the researc h laboratory for analysis.  
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  10.4 Tissue Banking  
 
Biologic specimens collected during the conduct of each clinical trial that are not used during the course of the study will 
be considered deliverables under the contract and thus the property of the NCI. At  study completion, NCI reserves the 
option to either retain or relinquish ownership of the unused biologic specimens. If NCI retains ownership of specimens, 
the Contractor shall collect, verify and transfer the requested biologic specimens from the site to  a NCI -specified 
repository or laboratory at NCI’s expense.  
 
11. REPORTING ADVERSE EVENTS   
 
DEFINITION: AE means any untoward medical occurrence associated with the use of a drug in humans, whether or not 
considered drug related. An AE can therefore be any unfavorable and unintended sign), symptom, or disease temporally 
associated with participation in a study, whether or not related to that participation. This includes all deaths that occur 
while a participant is on a study.  The participants in this stu dy will use the symptom diary to record their AEs.  
 
Please note that all abnormal clinical laboratory values that are determined to be of clinical significance based on a 
physician’s assessment are to be reported as AEs. Those labs determined to be of no clinical significance or of unknown 
clinical significance (per the physician’s assessment) should not be reported as AEs. Any lab value of unknown clinical 
significance should continue to be investigated/followed -up further for a final determination, if po ssible.  
 
A list of AEs that have occurred or might occur can be found in §6.2 Reported Adverse Event  AEs and Potential Risks , as 
well as the Investigator Brochure or package insert.  
 
11.1 Adverse Events  
 
11.1.1  Reportable AEs  
 
All AEs that occur after the  informed consent is signed and baseline assessments are completed (including run -in) must be 
recorded on the AE CR F (paper and/or electronic) whether or not related to study agent.  
 
11.1.2  AE Data Elements:  
 
The following data elements are required for AE reporting.  
• AE verbatim term  
• NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE  v4.0) AE term  (MedDRA lowest 
level term)  
• CTCAE ( MedDRA ) System Organ Class (SOC)  
• Event onset date and event ended date  
• Treatment assignment code ( TAC ) at time of AE onset  
• Severity grade  
• Attribution to study agent (relatedness)  
• Whether or not the event was reported as a SAE  
• Whether or not the subject dropped due to the event  
• Outcome of the event  
 
11.1.3  Severity of AEs  
   
11.1.3.1   Identify the AE using the CTCAE version 4.0. The CTCAE provides descriptive terminology (MedDRA 
lowest level term) and a grading scale for each AE listed. A copy of the CTCAE can be found at 
http://ctep.cancer.gov/protocolDevelopment/electronic applications/ctc.htm  
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  AEs will be assessed according to the grade associated with the CTCAE  term. AEs that do not have a corresponding 
CTCAE term will be assessed according to the general guid elines for grading used in the CTCAE v4.0. as stated below.  
 
CTCAE v4.0 general severity guidelines:  
 
Grade  Severity  Description  
1 Mild  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
2 Moderate  Moderate; minimal, local or noninvasive intervention indicated;  
limiting age -appropriate instrumental activities of daily living (ADL)*.  
3 Severe  Severe or medically significant but not immediately life -threatening;  
hospitalization or prolongatio n of hospitalization indicated; disabling; limiting self -
care ADL**.  
4 Life-threatening  Life-threatening consequences; urgent intervention indicated.  
5 Fatal  Death related to AE.  
   
ADL  
 
*Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, 
etc. 
 
**Self -care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not 
bedridden.  
 
11.1.4  Assessment of relationship of AE to treatment  
  
The possibility that the AE is related to study agent will be classified as one of the following: not related, unlikely, 
possible, probable, definite.  
  
11.1.5  Follow -up of AEs  
 
All AEs, including lab abnormalities that in the opinion of the investigator are clinically significant, will be followed 
according to good medical practices and documented as such.   
 
11.2 Serious Adverse Events   
 
11.2.1  DEFINITION : Regulations at 21 CFR §312.32 (revised April 1 , 2014)  defines an SAE as any  untoward medical 
occurrence that at any dose has one or more of the following outcomes : 
 
• Death 
• A life-threatening AE  
• Inpatient hospitalization or prolongation of existing  hospitalization 
• A persistent or significant incapacity or substantial disruption of the ability to perform normal life functions  
• A congenital anomaly or birth defect 
• Important medical events that may not be immediately life -threatening or result in death or 
hospitalization should also be considere d serious when, based upon appropriate medical judgment, they 
may jeopardize the patient and may require intervention to prevent one of the other outcomes.  
 
 
11.2.2  Reporting SAEs to DCP  
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  11.2.2.1   The Lead Organization and all Participating Organizations will report SAEs on the DCP SAE Report F orm 
found at http://prevention.cancer.gov/clinical -trials/clinical -trials -management/protocol -information -office/pio -
instructions -and-tools/2012 -consortia . 
 
11.2.2.2   Contact the DCP Medical Monitor  by phone or email (email is preferred) within 24 hours of knowledge of  
the event.  
 
DCP Medical Monitor:  
Eva Szabo , MD  
Chief  
Lung & Upper Aerodigestive Cancer Research Group  
Division of Cancer Prevention, NCI, NIH  
9609 Medical Center Drive, Room 5E -102, MSC 9781  
Bethesda, MD  20892 -9781 ( For FedEx, use Rockville, MD 20850)   
Phone:  (240) 276 -7011  
FAX:   (240) 276 -7848  
email:  szaboe@mail.nih.gov  
 
Include the following information when calling the Medical Monitor : 
• Date and time of the SAE  
• Date and time of the SAE report  
• Name of reporter  
• Call back phone number  
• Affiliation/Institution conducting the study  
• DCP protocol number  
• Title of protocol  
• Description of the SAE, including attribution to drug  
 
11.2.2.3   The Lead Organization and all Participating Organizations will email  written SAE reports to the DCP 
medical monitor and DCP’s Regulatory Cont ractor CCS Associates, Inc. (CCSA; phone: 650-691-4400)  at 
safety@ccsainc.com  within 48 hours of learning of the event using the fillable PDF SAE Report F orm.    
  
11.2.2.4   The DCP Medical Mon itor and CCSA regulatory  and safety  staff will determine which SAEs require 
FDA submission  as IND safety reports . 
 
11.2.2.5   The Lead Organization and all Participating Organizations will comply with applicable regulatory 
requirements related to reporting SAEs to t he IRB/IEC.  
 
11.2. 3 Follow -up of SAE  
 
Site staff should send follow -up reports as requested when additional information is available. Additional information 
should be entered on the DCP SAE Report F orm in the appropriate format. Follow -up information shou ld be sent to DCP 
as soon as available. SAE related to the study agent will be followed until resolved, or deemed unlikely to further resolved 
by the Protocol Chair, or until the subject withdraws consent for further follow -up. SAE unrelated or unlikely to  be related 
to study agent will be followed for at least 30 days after the last dose of study agent.  
 
12. STUDY MONITORING  
 
 
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  12.1 Data Management  
 
This study will report clinical data using the OnCore application from Forte Research Systems, Inc., as stated in the 
Master Data Management Plan.  All users of the database will have appropriate education, training and experience to 
perform assigned tasks .  The data collection and management will be done according to the Consortia 2012 DMP.  
 
12.2 Case Report Forms  
 
Participant data will be collected using protocol -specific case report forms (CRF) developed from the standard set of DCP 
Chemoprevention CRF T emplates and utilizing NCI -approved Common Data Elements (CDE). The approved CRFs will 
be used to create the electronic CRF (e -CRF) screens in the OnCore application. Site staff will enter data into the e -CRF 
for transmission to DCP according to pre -establ ished DCP standards and procedures. Amended CRF will be submitted to 
the DCP Protocol Information Office for review and approval.  Approved changes will be programmed into the OnCore 
database by the Consortium Data Management staff.   
 
12.3 Source Documents  
 
Source documentation for this trial will consist of protocol -specific source documents as well as clinical and research 
laboratory reports.  In the event of a Serious Adverse Event, medical records related to the event will be sought for source 
documenta tion of the event and its treatment, if any.  
 
 
12.4 Data and Safety Monitoring Plan  
 
The University of Arizona Cancer Center (UACC) Data and Safety Monitoring Board (DSMB) will ensure subject safety 
by coordinating, monitoring, and providing oversight for study data and subject safety for all UA Consortium clinical 
trials consistent with the National Institutes of Health Policy for Data and Safety Monitoring dated June 10, 1998; further 
guidance statement issued by the NIH on June 5, 2000, and the policy fo r Data and Safety Monitoring by Data and Safety 
Monitoring Boards.  Data from this study will be monitored by the UACC DSMB every six months.  
 
Regular monthly meetings of the UA Consortium, are used as a forum to review accrual rates, problematic issues re lating 
to accrual and protocol implementation, AEs occurrence, follow -up, and reporting; submission of all required study 
reports; and progress and outcomes of laboratory analyses.   
 
12.5 Sponsor or FDA Monitoring  
 
The NCI, DCP (or their designee), pharmaceutical collaborator (or their designee), or FDA may monitor/audit various 
aspects of the study. These monitors will be given access to facilities, databases, supplies and records to review and verify  
data pertinent  to the study.  
 
12.6 Record Retention  
 
Clinical records for all participants, including CRFs, all source documentation (containing evidence to study eligibility, 
history and physical findings, laboratory data, results of consultations, etc.), as well as IRB records and other regulatory 
documentation will be retained by the Investigator in a secure storage facility in compliance with Health Insurance 
Portability and Accountability Act (HIPAA), Office of Human Research Protections (OHRP), Foo d and Drug 
Administration (FDA) regulations and guidances, and NCI/DCP requirements, unless the standard at the site is more 
stringent. The records for all studies performed under an IND will be maintained, at a minimum, for two years after the 
approval of  a New Drug Application (NDA). For NCI/DCP, records will be retained for at least three years after the 
completion of the research. NCI will be notified prior to the planned destruction of any materials. The records should be 
accessible for inspection and copying by authorized persons of the Food and Drug Administration. If the study is done 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  outside of the United States, applicable regulatory requirements for the specific country participating in the study also 
apply.  
 
12.7 Cooperative Research and Developm ent Agreement (CRADA)/Clinical Trials Agreement (CTA)  
 
Not applicable . 
 
13. STATISTICAL CONSIDER ATIONS  
 
13.1 Study Design/Description  
 
This is an open -label, randomized cross -over study to determine whether two different doses of Avmacol®  (4 tablets  per 
day for 10 -14 days; 8 tablets  per day for 10 -14 days) increase the detoxification of tobacco carcinogens in otherwise 
healthy, current smokers. Participants will serve as their own controls  based on a 2 x 2 cross -over design . Specifically, 
each participant will have two Intervention Periods (one period taking 4 tablets  per day; the other taking 8 tablets  per day) 
with a 10 -14 day washout period in between to eliminate the potential carry -over effect.  
 
 
13.2 Randomization/ Stratification  
 
Each participant will be randomly assigned, based on random allocation rule,  to either receiving 4 tablets  per day first and 
then 8  tablets  per day or receiving 8 tablets  per day first and then 4  tablets  per day to eliminate the dose sequence effect. 
No stratification or blocking  will be performed.  
 
13.3 Accrual and Feasibility  
 
We plan to accrue 61 eligible participants to initiate agent intervention. With an anticipated attrition rate of 33% or less 
(with respect to completing the intervention and having complete endpoint data), we expect to have at least 4 1 participants 
with evaluable endpoint data.  Projected  accrual is 2 participants per month.  
 
13.4 Primary Objective, Endpoint(s) , Analysis Plan  
 
The primary objective of this study is to  determine whether Avmacol® increases the urinary excretion of the mercapturic 
acid of the tobacco carcinogen, benzene , in healthy current smokers. The primary endpoint is the change (from baseline to 
end-of-intervention for each Intervention Period) in the mercapturic acid of benzene  after Avmacol® intervention. The 
changes following 4 tablets of Avmacol® per day and after 8 tablets of Avmacol® per day will be determined separately. 
Two-sided paired t tests will be performed to evaluate whether the changes are significantly. Bonferroni correction will be 
used to correct for multiple co mparisons ( two dose levels ). With a sample size of 4 1 and an overall significance level of 
5% (based on Bonferroni correction, i.e. a 2.5% significance level for each test), th ere will be at least 80% power to detect 
an effect size of 0.50 standard deviations.  This is in line with an effect size of 0.45 standard deviations for a similar study  
(49).  
 
13.5 Secondary Objectives, Endpoints, Anal ysis Plans  
 
The secondary objectives include to determine whether Avmacol®  increases  the mercapturic acids of acrolein and 
crotonaldehyde  and the mercapturc acids of tobacco carcinogens normalized by bio -measurement of tobacco exposure  and 
upregulates the NRF2 target gene transcripts in the buccal cells of current smokers and to evaluate for a dose -response 
relationship between Avmacol®  and the detoxification of tobacco carcinogens and the expression of NRF2 target gene 
transcripts  and the relationship between systemic study agent exposure and biomarker modulation . The secondary 
endpoints are the changes in mercapturic acids of acrolein and crotonaldehyde levels (from baseline to end -of-intervention 
for each Intervention Period) , the ch anges in mercapturic acids of tobacco carcinogens, normalized by bio -measurement 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  of tobacco exposure  (from baseline to end -of-intervention for each Intervention Period) and in NRF2 target gene 
transcripts (from baseline to day 4 -8 and to end -of-interventio n for each Intervention Period ) assessed by the expression of 
NQO1 after Avmacol®  intervention. Similar to the primary endpoint, each of the changes following 4 tablets of 
Avmacol® per day and after 8 tablets of Avmacol® per day will be evaluated separate ly. For changes in tobacco 
carcinogens , two-sided paired t tests  will be performed to evaluate the significance of changes . For changes in NRF2 
target gene transcripts, linear mixed effects models will be fitted to evaluate the significance of changes sinc e each 
participant will have two changes in each Intervention Period ( from baseline to day 4 -8 and to end -of-intervention ). 
Linear mixed effects models will be also fitted to determine whether there  is a dose -response relationship between the 
Avmacol® dose and the change in carcinogen metabolites and the change in the NRF2 target gene transcripts since each 
participant will have more than one change for each endpoint.  Spearman correlation coefficient will be calculated to 
evaluate the correlation between systemic study agent exposure  and biomarker modulation . 
 
In addition, we will also explore whether the GSTM1  and GSTT1  genotypes are important genetic modulators of 
detoxi fication of tobacco carcinogens . This will be evaluated by comparing the change in benzene for each dose level  
between GSTM1 -null and GSTM1 -positive subjects and between GSTT1 -null and GSTT1 -positive subjects, respectively, 
using two -sided two -sample t tests. For all of the secondary an d exploratory analyses, adjustment for multiple 
comparisons will not be performed. However, the number of comparisons will be reported and we will also cautiously 
interpret the findings. For both primary and secondary endpoints, two-sample t tests will be performed to evaluate whether 
there is a significant sequence effect (e.g. receiving 4 tablets  per day in the first Intervention Period vs. receiving 4 tablets  
per day in the second Intervention Period  and receiving 8 tablets  per day in the first Intervent ion Period vs. receiving 8 
tablets  per day in the second Intervention Period ). Regression techniques will be used to control for baseline levels and 
potential confounders if necessary. Also, if the normality assumption is violated, potential transformation  will be sought 
or nonparametric methods such as sign ed rank test will be performed. For any of the endpoints, if a missing rate of >15% 
is observed, multiple imputation by chained equations will be performed.  
 
 
13.6 Reporting  and Exclusions  
 
Participants will be considered compliant for statistical analysis if they have taken  80% of their assigned study doses 
based on count of return  pills. 
 
13.7 Evaluation of Toxicity  
 
All participants will be evaluable for toxicity from the time of their f irst dose o f Avmacol® . Descriptive statistics of the 
type and frequency of all AEs will be generated, including 95 confidence intervals.  
 
13.8 Evaluation of Response  
 
All subjects with endpoint data will be assessed for response to intervention, based on t he endpoints described above in 
Sections 13.4 and 13.5.  
 
Sub-analyses may be performed on the subsets of participants, excluding those for whom major protocol deviations have 
been identified (e.g., early discontinuation of intervention, major protocol viol ations, etc.).  However, sub -analyses may 
not serve as the basis for drawing conclusions concerning efficacy, and the reasons for excluding participants from the 
analysis should be clearly reported.  
 
13.9 Interim Analysis  
 
No formal interim statistical analyses  are planned for this trial.  Accrual, data collection, and any AEs will be monitored 
on a regular basis.  
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  13.10  Ancillary Studies  
 
None.  
 
14. ETHICAL AND REGULATO RY CONSIDERATIONS  
 
14.1 Form FDA 1572  
 
Prior to initiating this study, the Protocol L ead Investigator at the Lead or Participating Organization(s)  will provide a 
signed Form FDA 1572 stating that the study will be conducted in compliance with regulations for clinical investigations 
and listing the investigators, at each site that will part icipate in the protocol.  All personnel directly involved in the 
performance of procedures required by the protocol and the collection of data should be listed on Form FDA 1572.  
 
14.2 Other Required Documents  
 
14.2.1  Current (within two years) CV or biosketch for all study personnel  listed on the Form FDA 1572  and Delegation 
of Tasks form  for the Lead Organization and all Participating Organizations.  
 
14.2.2  Current medical licenses (where applicable) for all study per sonnel listed on Form FDA 1572 and Delegation of 
Tasks form for the Lead Organization and all Participating Organizations.  
 
14.2.3  Lab certification ( e.g., CLIA, CAP) and lab normal ranges for all labs listed on Form FDA 1572 for the Lead 
Organization and all Participating Organizations.  
 
14.2.4  Documentation of training in “Protection of Human Research Subjects” for all study personnel  listed on the FDA 
Form 1572 and Delegation of Tasks form for the Lead Organization and all Participating Organizations.  Documentation  
of “Good Clinical Practice” training is required for all study personnel listed on the FDA Form 1572.  
 
14.2.5  Documentation of Federalwide Assurance (FWA) number for the Lead Organization and all Participating 
Organizations.  
 
14.2.6  Signed Investigator’s Brochure /Packa ge Insert acknowledgement form  
 
14.2.7  Delegation of Tasks form  for the Lead Organization and all Participating Organizations signed by the Principal 
Investigator for each site and initialed by all study personnel listed on the form  
 
14.2.8  Signed and dated NCI, DCP Fin ancial Disclosure  Form for all study personnel listed on Form FDA 1572 for the 
Lead Organization and all Participating Organizations  
 
14.3 Institutional Review Board Approval  
 
Prior to initiating the study and receiving agent, the Investigators at the Lead  Organization and the Participating 
Organization(s) must obtain written approval to conduct the study from the appropriate IRB. Should changes to the study 
become necessary, protocol amendments will be submitted to the DCP PIO according to DCP Amendment Gu idelines. 
The DCP -approved amended protocol must be approved by the IRB prior to implementation  
 
14.4 Informed Consent  
 
All potential study participants will be given a copy of the IRB -approved Informed Consent to review. The investigator 
will explain all aspects of the study in lay language and answer all questions regarding the study. If the participant decide s 
to partici pate in the study, he/she will be asked to sign and date the Informed Consent document. The study agent(s) will 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  not be released to a participant who has not signed the Informed Consent document. Subjects who refuse to participate or 
who withdraw from the s tudy will be treated without prejudice.  
 
Participants must be provided the option to allow the use of blood samples, other body fluids, and tissues obtained during 
testing, operative procedures, or other standard medical practices for further research purp oses. If applicable, statement of 
this option may be included within the informed consent document or may be provided as an addendum to the consent. A 
Model Consent Form for Use of Tissue for Research is available through a link in the DCP website.  
 
Prior to study initiation, the informed consent document must be reviewed and approved by NCI, DCP, the Consortium 
Lead Organization, and the IRB at each Organization at which the protocol will be implemented. Any subsequent changes 
to the informed consent must be approved by NCI, DCP, the Consortium Lead Organization’s IRB, and then submitted to 
each organization’s IRB for approval prior to initiation.  
 
14.5 Submission of Regulatory Documents  
 
All regulatory documents are collected by the Consortia Lead Organiza tion and reviewed for completeness and accuracy. 
Once the Consortia Lead Organization has received complete and accurate documents from a participating organization, 
the Consortium Lead Organization will forward the regulatory documents to DCP ’s Regulatory  Contractor:  
 
 Paper Document/CD -ROM Submissions : 
 Regulatory Affairs  Department  
 CCS Associates , Inc.  
 2001 Gateway Pla ce 
 Suite 350 West  
 San Jose, CA 95110  
 Phone: 650 -691-4400  
 Fax: 650 -691-4410  
 
 E-mail Submissions : 
 regulatory@ccsainc.com  
 
Regulatory documents that do not require an original signature may be sent electronically to the Consortium Lead 
Organization for review, which will then be electronically forwarded to DCP ’s Regulatory Contractor.  
 
 
14.6 Other  
 
This trial will be conducted in compliance with the protocol, Good Clinical Practice (GCP), and the applicable regulatory 
requirements.  
 
15. FINANCING, EXPENSES,  AND/OR INSURANCE  
 
Study procedures performed during study visits will be covered by the study budget.  Research tests, including biomarker 
evaluations, will not be billed to the subject. Subjects may incur minimal out -of-pocket expenses for transportation but 
will not be ch arged for study agent or any study -related activities. If subjects  complete the study, they  will receive a total 
of $525, to  be used at their discretion for out of pocket cost such as transportation. If they do not complete the stu dy, the 
amount will be prorated for completed visits as follows: $ 75 for Visit 2, $50 for Visit 3, $100 for Visit 4, $50 for Visits 5 
and 6, and $200 for Visit 7.  If injury occurs, medical care will be provided and charged to the subject’s insurer.  
 
 
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  REFERENCES  
 
1. Leon X, Quer M, Diez S, Orus C, Lopez -Pousa A, and Burgues J. Second neoplasm in patients with head and 
neck cancer. Head & neck.  1999;21(3):204 -10. 
2. Lee DH, Roh JL, Baek S, Jung JH, Choi SH, Nam SY, et al. Second cancer incidence, risk factor, a nd specific 
mortality in head and neck squamous cell carcinoma. Otolaryngology --head and neck surgery : official journal of 
American Academy of Otolaryngology -Head and Neck Surgery.  2013;149(4):579 -86. 
3. Day GL, Blot WJ, Shore RE, McLaughlin JK, Austin DF , Greenberg RS, et al. Second cancers following oral and 
pharyngeal cancers: role of tobacco and alcohol. Journal of the National Cancer Institute.  1994;86(2):131 -7. 
4. Lippman SM, and Hong WK. Second malignant tumors in head and neck squamous cell carcino ma: the 
overshadowing threat for patients with early -stage disease. International journal of radiation oncology, biology, 
physics.  1989;17(3):691 -4. 
5. Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM, et al. The impact of smoking status, disease s tage, 
and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid 
chemoprevention trial. Cancer epidemiology, biomarkers & prevention : a publication of the American 
Association for Cancer Research, cosponsored  by the American Society of Preventive Oncology.  2001;10(8):823 -
9. 
6. Gilpin EA, and Pierce JP. Demographic differences in patterns in the incidence of smoking cessation: United 
States 1950 -1990. Ann Epidemiol.  2002;12(3):141 -50. 
7. Slaughter DP, Southwick HW, and Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical 
implications of multicentric origin. Cancer.  1953;6(5):963 -8. 
8. Chainani -Wu N. Diet and oral, pharyngeal, and esophageal cancer. Nutrition and cancer.  2002;44(2):104 -26. 
9. Pavia M, Pileggi C, Nobile CG, and Angelillo IF. Association between fruit and vegetable consumption and oral 
cancer: a meta -analysis of observational studies. The American journal of clinical nutrition.  2006;83(5):1126 -34. 
10. Day GL, Shore RE, Blot WJ, McLaughlin JK, Austin DF, Greenberg RS, et al. Dietary factors and second 
primary cancers: a follow -up of oral and pharyngeal cancer patients. Nutrition and cancer.  1994;21(3):223 -32. 
11. Bravi F, Bosetti C, Filomeno M, Levi F,  Garavello W, Galimberti S, et al. Foods, nutrients and the risk of oral and 
pharyngeal cancer. British journal of cancer.  2013;109(11):2904 -10. 
12. Fowke JH. Head and neck cancer: a case for inhibition by isothiocyanates and indoles from cruciferous 
vegetables. European journal of cancer prevention : the official journal of the European Cancer Prevention 
Organisation.  2007;16(4):348 -56. 
13. Burge -Bottenbley A, and Shklar G. Retardation of experimental oral cancer development by retinyl acetate. 
Nutrition and cancer.  1983;5(3 -4):121 -9. 
14. Lippman SM, Garewal HS, and Meyskens FL, Jr. Retinoids as potential chemopreventive agents in squamous cell 
carcino ma of the head and neck. Preventive medicine.  1989;18(5):740 -8. 
15. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13 -cis-retinoic acid in the treatment of oral 
leukoplakia. The New England journal of medicine.  1986;315(24):1501 -5. 
16. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with 
isotretinoin in squamous -cell carcinoma of the head and neck. The New England journal of medicine.  
1990;323(12):795 -801. 
17. Khuri FR, Lee JJ, Lippman S M, Kim ES, Cooper JS, Benner SE, et al. Randomized phase III trial of low -dose 
isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. Journal of 
the National Cancer Institute.  2006;98(7):441 -50. 
18. Leeman -Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, et al. Inhibition of EGFR -
STAT3 signaling with erlotinib prevents carcinogenesis in a chemically -induced mouse model of oral squamous 
cell carcinoma. Cancer prevention research.  2011;4(2):23 0-7. 
19. Perkins TM, and Shklar G. Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin. Oral 
surgery, oral medicine, and oral pathology.  1982;53(2):170 -8. 
20. Cornwall H, Odukoya O, and Shklar G. Oral mucosal tumor inhibition by ibupro fen. Journal of oral and 
maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.  
1983;41(12):795 -800. 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  21. Tanaka T, Nishikawa A, Mori Y, Morishita Y, and Mori H. Inhibitory effects of non -steroidal anti -inflammatory 
drugs, piroxicam and indomethacin on 4 -nitroquinoline 1 -oxide -induced tongue carcinogenesis in male ACI/N 
rats. Cancer letters.  1989;48(3):177 -82. 
22. Shiotani H, Denda A, Yamamoto K, Kitayama W, Endoh T, Sasaki Y, et al. Increased expression of 
cyclooxygenase -2 protein in 4 -nitroquinoline -1-oxide -induced rat tongue carcinomas and chemopreventive 
efficacy of a specific inhibitor, nimesulide. Cancer research.  2001;61(4):1451 -6. 
23. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, et al . Stratifying the risk of NSAID -related 
upper gastrointestinal clinical events: results of a double -blind outcomes study in patients with rheumatoid 
arthritis. Gastroenterology.  2002;123(4):1006 -12. 
24. Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoul ou VA, Van Waes C, Rudy S, et al. Randomized, 
double -blind, placebo -controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in 
oropharyngeal leukoplakia. Clinical cancer research : an official journal of the American Associati on for Cancer 
Research.  2004;10(5):1565 -73. 
25. Bertagnolli MM. Chemoprevention of colorectal cancer with cyclooxygenase -2 inhibitors: two steps forward, one 
step back. The Lancet Oncology.  2007;8(5):439 -43. 
26. Papadimitrakopoulou VA, William WN, Jr., Dan nenberg AJ, Lippman SM, Lee JJ, Ondrey FG, et al. Pilot 
randomized phase II study of celecoxib in oral premalignant lesions. Clinical cancer research : an official journal 
of the American Association for Cancer Research.  2008;14(7):2095 -101. 
27. Saba NF, H urwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, et al. Chemoprevention of head and neck cancer with 
celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer prevention research.  
2014;7(3):283 -91. 
28. Prochaska HJ, Santamaria AB, and Ta lalay P. Rapid detection of inducers of enzymes that protect against 
carcinogens. Proceedings of the National Academy of Sciences of the United States of America.  1992;89(6):2394 -
8. 
29. Kensler TW. Chemoprevention by inducers of carcinogen detoxication enz ymes. Environmental health 
perspectives.  1997;105 Suppl 4:965 -70. 
30. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2/small Maf heterodimer mediates the 
induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochemical and 
biophysical research communications.  1997;236(2):313 -22. 
31. Zhang Y, and Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. 
Acta pharmacologica Sinica.  2007;28(9):1343 -54. 
32. Hong F, Fre eman ML, and Liebler DC. Identification of sensor cysteines in human Keap1 modified by the cancer 
chemopreventive agent sulforaphane. Chemical research in toxicology.  2005;18(12):1917 -26. 
33. Kensler TW, Egner PA, Agyeman AS, Visvanathan K, Groopman JD, Ch en JG, et al. Keap1 -nrf2 signaling: a 
target for cancer prevention by sulforaphane. Topics in current chemistry.  2013;329:163 -77. 
34. Fahey JW, Zhang Y, and Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that 
protect against chemical carcinogens. Proceedings of the National Academy of Sciences of the United States of 
America.  1997;94(19):10367 -72. 
35. Kensler TW, Chen JG, Egner PA, Fahey JW, Jacobson LP, Stephenson KK, et al. Effects of glucosinolate -rich 
broccoli sprouts on urinary levels of aflatoxin -DNA adducts and phenanthrene tetraols in a randomized clinical 
trial in He Zuo township, Qidong, Peopl e's Republic of China. Cancer epidemiology, biomarkers & prevention : a 
publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive 
Oncology.  2005;14(11 Pt 1):2605 -13. 
36. Egner PA, Chen JG, Wang JB, Wu Y,  Sun Y, Lu JH, et al. Bioavailability of Sulforaphane from two broccoli 
sprout beverages: results of a short -term, cross -over clinical trial in Qidong, China. Cancer prevention research.  
2011;4(3):384 -95. 
37. Kensler TW, Ng D, Carmella SG, Chen M, Jacobson  LP, Munoz A, et al. Modulation of the metabolism of 
airborne pollutants by glucoraphanin -rich and sulforaphane -rich broccoli sprout beverages in Qidong, China. 
Carcinogenesis.  2012;33(1):101 -7. 
38. Egner PA, Chen JG, Zarth AT, Ng DK, Wang JB, Kensler KH, et al. Rapid and sustainable detoxication of 
airborne pollutants by broccoli sprout beverage: results of a randomized clinical trial in China. Cancer prevention 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  research.  2014;7(8):813 -23. 
39. Bauman JE, Zang Y, Sen M, Li C, Wang L, Egner PA, et al. Preven tion of Carcinogen -Induced Oral Cancer by 
Sulforaphane. Cancer prevention research.  2016;9(7):547 -57. 
40. Shapiro TA, Fahey JW, Wade KL, Stephenson KK, and Talalay P. Chemoprotective glucosinolates and 
isothiocyanates of broccoli sprouts: metabolism and ex cretion in humans. Cancer epidemiology, biomarkers & 
prevention : a publication of the American Association for Cancer Research, cosponsored by the American 
Society of Preventive Oncology.  2001;10(5):501 -8. 
41. Shapiro TA, Fahey JW, Dinkova -Kostova AT, Hol tzclaw WD, Stephenson KK, Wade KL, et al. Safety, 
tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. 
Nutrition and cancer.  2006;55(1):53 -62. 
42. Fahey JW, Talalay P, and Kensler TW. Notes from the fie ld: "green" chemoprevention as frugal medicine. 
Cancer prevention research.  2012;5(2):179 -88. 
43. Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, et al. Sulforaphane inhibits 
extracellular, intracellular, and antibiotic -resistant str ains of Helicobacter pylori and prevents benzo[a]pyrene -
induced stomach tumors. Proceedings of the National Academy of Sciences of the United States of America.  
2002;99(11):7610 -5. 
44. Xu C, Huang MT, Shen G, Yuan X, Lin W, Khor TO, et al. Inhibition of 7, 12-dimethylbenz(a)anthracene -
induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2 -related factor 2. 
Cancer research.  2006;66(16):8293 -6. 
45. Cornblatt BS, Ye L, Dinkova -Kostova AT, Erb M, Fahey JW, Singh NK, et al. Pr eclinical and clinical evaluation 
of sulforaphane for chemoprevention in the breast. Carcinogenesis.  2007;28(7):1485 -90. 
46. Zhang Y, Kensler TW, Cho CG, Posner GH, and Talalay P. Anticarcinogenic activities of sulforaphane and 
structurally related synthet ic norbornyl isothiocyanates. Proceedings of the National Academy of Sciences of the 
United States of America.  1994;91(8):3147 -50. 
47. Ramos -Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, et al. Sensitivity to carcinogenesis is 
increased and ch emoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor -deficient mice. 
Proceedings of the National Academy of Sciences of the United States of America.  2001;98(6):3410 -5. 
48. Ohkoshi A, Suzuki T, Ono M, Kobayashi T, and Yamamoto M. Roles of Keap1 -Nrf2 system in upper 
aerodigestive tract carcinogenesis. Cancer prevention research.  2013;6(2):149 -59. 
49. Yuan JM, Stepanov I, Murphy SE, Wang R, Allen S, Jensen J, et al. Clinical Trial of 2 -Phenethyl Isothiocyanate 
as an Inhibitor of Meta bolic Activation of a Tobacco -Specific Lung Carcinogen in Cigarette Smokers. Cancer 
prevention research.  2016;9(5):396 -405. 
50. Shapiro TA, Fahey JW, Wade KL, Stephenson KK, and Talalay P. Human metabolism and excretion of cancer 
chemoprotective glucosinol ates and isothiocyanates of cruciferous vegetables. Cancer epidemiology, biomarkers 
& prevention : a publication of the American Association for Cancer Research, cosponsored by the American 
Society of Preventive Oncology.  1998;7(12):1091 -100. 
51. Fahey JW,  Zalcmann AT, and Talalay P. The chemical diversity and distribution of glucosinolates and 
isothiocyanates among plants. Phytochemistry.  2001;56(1):5 -51. 
52. Brooks JD, Paton VG, and Vidanes G. Potent induction of phase 2 enzymes in human prostate cells by  
sulforaphane. Cancer Epidemiol Biomarkers Prev.  2001;10(9):949 -54. 
53. Myzak MC, Tong P, Dashwood WM, Dashwood RH, and Ho E. Sulforaphane retards the growth of human PC -3 
xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood).  2007;232(2):227 -34. 
54. Jones SB, and Brooks JD. Modest induction of phase 2 enzyme activity in the F -344 rat prostate. BMC Cancer.  
2006;6:62.  
55. Zhang Y, Munday R, Jobson HE, Munday CM, Lister C, Wilson P, et al. Induction of GST and NQO1 in cultured 
bladde r cells and in the urinary bladders of rats by an extract of broccoli (Brassica oleracea italica) sprouts. J 
Agric Food Chem.  2006;54(25):9370 -6. 
56. Yoxall V, Kentish P, Coldham N, Kuhnert N, Sauer MJ, and Ioannides C. Modulation of hepatic cytochromes 
P450 and phase II enzymes by dietary doses of sulforaphane in rats: Implications for its chemopreventive activity. 
Int J Cancer.  2005;117(3):356 -62. 
57. Seow A, Shi CY, Chung FL, Jiao D, Hankin JH, Lee HP, et al. Urinary total isothiocyanate (ITC) in a population -
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  based sample of middle -aged and older Chinese in Singapore: relationship with dietary total ITC and glutathione 
S-transferase M1/T1/P1 genotypes. Cancer Epidemiol Biomarkers Prev.  1998;7(9):775 -81. 
58. Nugon -Baudon L, Rabot, S. Glucosinolates an d glucosinolate derivates: implications for protection against 
chemical carcinogenesis. Nutr Res Rev.  1994;7(1):205 -31. 
59. Milford GFJ, Evans, E.J. Factors causing variation in glucosinolates in oilseed rape. Outlook Agric.  1991;20:31 -7. 
60. Mullin WJ, Sa hasrabudhe, H.R. An estimate of the average daily intake of glucosinolate. Nutr Rep Int.  
1978;18:273 -9. 
61. Wattenberg LW, Hanley, A.B., Barany, G., Sparnins, V.L., Lam, L.K.T., Fenwick, G.R. . In: Hayashi Y ed. Diet, 
Nutrition and Cancer . Tokyo: Japan Sci ence Society Press; 1986:193 -203. 
62. Murashima M, Watanabe S, Zhuo XG, Uehara M, and Kurashige A. Phase 1 study of multiple biomarkers for 
metabolism and oxidative stress after one -week intake of broccoli sprouts. Biofactors.  2004;22(1 -4):271 -5. 
63. Riedl MA, Saxon A, and Diaz -Sanchez D. Oral sulforaphane increases Phase II antioxidant enzymes in the human 
upper airway. Clin Immunol.  2009;130(3):244 -51. 
64. Christiansen B, Bellostas Muguerza N, Petersen AM, Kveiborg B, Madsen CR, Thomas H, et al. Inge stion of 
broccoli sprouts does not improve endothelial function in humans with hypertension. PloS one.  2010;5(8):e12461.  
65. Bahadoran Z, Mirmiran P, Hosseinpanah F, Rajab A, Asghari G, and Azizi F. Broccoli sprouts powder could 
improve serum triglyceride and oxidized LDL/LDL -cholesterol ratio in type 2 diabetic patients: a randomized 
double -blind placebo -controlled clinical trial. Diabetes Res Clin Pract.  2012;96(3):348 -54. 
66. Alumkal JJ, Slottke R, Schwartzman J, Cherala G, Munar M, Graff JN, et al. A ph ase II study of sulforaphane -
rich broccoli sprout extracts in men with recurrent prostate cancer. Invest New Drugs.  2015;33(2):480 -9. 
67. Carmella SG, Chen M, Zarth A, and Hecht SS. High throughput liquid chromatography -tandem mass 
spectrometry assay for m ercapturic acids of acrolein and crotonaldehyde in cigarette smokers' urine. Journal of 
chromatography B, Analytical technologies in the biomedical and life sciences.  2013;935:36 -40. 
68. Haiman CA, Patel YM, Stram DO, Carmella SG, Chen M, Wilkens LR, et al . Benzene Uptake and Glutathione S -
transferase T1 Status as Determinants of S -Phenylmercapturic Acid in Cigarette Smokers in the Multiethnic 
Cohort. PloS one.  2016;11(3):e0150641.  
69. Egner PA, Kensler TW, Chen JG, Gange SJ, Groopman JD, and Friesen MD. Qu antification of sulforaphane 
mercapturic acid pathway conjugates in human urine by high -performance liquid chromatography and isotope -
dilution tandem mass spectrometry. Chemical research in toxicology.  2008;21(10):1991 -6. 
70. Piller M, Gilch G, Scherer G, and Scherer M. Simple, fast and sensitive LC -MS/MS analysis for the simultaneous 
quantification of nicotine and 10 of its major metabolites. Journal of chromatography B, Analytical technologies 
in the biomedical and life sciences.  2014;951 -952:7 -15. 
71. Kelsey KT, Nelson HH, Wiencke JK, Smith CM, and Levin S. The glutathione S -transferase theta and mu 
deletion polymorphisms in asbestosis. Am J Ind Med.  1997;31(3):274 -9. 
72. Alberts D, Ranger -Moore J, Einspahr J, Saboda K, Bozzo P, Liu Y, et al. Safety and e fficacy of dose -intensive 
oral vitamin A in subjects with sun -damaged skin. Clinical cancer research : an official journal of the American 
Association for Cancer Research.  2004;10(6):1875 -80. 
73. Bartels PH, Krouse RS, Prasad AR, Yozwiak M, Liu Y, Bartels HG, et al. Actinic damage in histopathologically 
normal skin. Anal Quant Cytol Histol.  2008;30(6):316 -22.  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  CONSENT FORM  
 
Study Title for Study Participants:  
Testing the effect of Avmacol® on the cancer causing substances of tobacco in heavy smokers  
 
Official Study Title for Internet Search on http://www.ClinicalTrials.gov :  
Clinical Study of Avmacol® for Detoxification of Tobacco Carcinogens in Heavy Smokers  
 
Introduction  
 
This is a clinical trial, a type of research study. Your study doctor will explain the clinical trial to you. Clinical trials  
include only people who choose to take part in the research. Please take your time to make your decision about 
volunteering. You m ay discuss your decision with your friends and family. You can also discuss this study with your 
health care team. If you have any questions, you can ask your study doctor for more of an explanation. You should only 
agree to participate in this study when you are comfortable enough with the information so that you can make an informed 
decision about joining.  
What is the usual approach to my status as a current smoker?  
You are being asked to take part in this study because you are a current smoker. Smokers a re at increased risk for  
developing lung , head and neck,  and other cancers. Current smokers who do not take part in this study are usually 
followed closely by their doctor to watch for the development of cancer and may be offered help in stopping smoking.   
 
What are my other choices if I do not take part in this study?  
If you decide not to take part in this study, you have other choices. For example:  
• you may choose to have the usual approach described above,  
• you may choose to take part in a different stud y, if one is available,  
• or you may choose to do nothing.  
 
Why is this study being done?   
The purpose of this study is to see if Avmacol® , a dietary supplement made from broccoli sprout and seed extract powder, 
can break down some of the cancer causing sub stances in tobacco  smoke and produce substances that may protect cells 
from tobacco smoke -induced damage in current  smokers.   The study will also study inner nose and cheek cells for damage 
from tobacco smoke, and see if the genetic type of a certain detoxification enzyme affects the amount of  cancer causing 
substances in tobacco  that are broken down . As a dietary supplement, Avmaco l® is not approved by the Food and Drug 
Administration for use in the treatment or prevention of disease . Its use in this study is investigational.  The study is 
sponsored by the National Cancer Institute.  
 
What are the study groups?   
This study has two study groups. Group 1 will receive the study drug , Avmacol® , at a lower dose and then increase to a 
higher dose after a washout period (a period of  not taking the study drug) . Group 2 will first receive Avmacol®  at a higher 
dose and then will decrease to a  lower dose after a washout period.  Approximately 61 subjects will participate in this 
study.  
 
A computer will randomly put you in a study group —like a coin toss —to decide what group you get placed into. Once 
you are put in a group, you cannot switch to th e other group.  
  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016   
 
 
 
 
 
 
 
How long will I be in this study?  
You will be in the study for around 8 - 12 weeks. You will take Avmacol®  for a period of 10 -14 days, followed by a 10-
14 day washout period  (a period of not taking the study drug) , and then take Avmacol®  for another period of 10 -14 
days. Each period could be extended up to  21 days if there was any scheduling difficulties.  Even if you do not finish the 
study, your doctor will continue to watch you for side effects and follow your condition for  10-14 days.  
 
What extra tests and procedures will I have if I take part in this study?  
Before you begin the study:  
 
You will need to have the following procedures to find out if you can be in the study  at a screening visit  (Visit 1) :  
• The study staff will go over this consent form and answer any questions you may have. Once you have signed it, 
the following procedures will be done.  
• Brief physical exam including vital signs (height, weight, blood pressure, pulse and temperature).  A cli nician 
will listen to your heart and lungs and check your abdomen.  
• Collection of approximately 2½ teaspoons of blood for routine laboratory tests.  
• A review of your medical history and current medications.  
• You will be given a questionnaire to complete about  your past and current tobacco  and alcohol  use. It will take 
about 10 minutes to complete.  
• Urine pregnancy test if you are a woman who could become pregnant.  
• You will be given a s ymptom diary to record any illness or injury during the study.  
• You will be given a urine collection kit consisting of the supplies and instructions to collect an overnight urine 
sample the night before your next visit to bring with you to the visit . This is done to measure the amount of 
substances  from tobacco exposur e and substances from Avmacol ® in your urine.  
 
If the exams, tests, and procedures show that you can take part in the study, and you choose to, then you will need the 
following extra procedures.  
 
Intervention period 1 Baseline Visit (Start of study , Visi t 2): You will be assigned to Study Group 1 or 2.  Tests and 
procedures include:  
• You will turn in your overnight urine collection .  
• Vital signs (weight, blood pressure, pulse and temperature).  
• Urine pregnancy test if you are a woman who could become pregnant.  
• A review of your symptom diary  and current medications . 
• You will be asked about your tobacco use  since the previous visit.  
• Collection of approximately 2½ teaspoons  of blood for research  tests (to determine the genetic type of a certain 
detoxifica tion enzyme) .  
• Collection of cells from your nose  (to determine cellular damage from tobacco exposure) . We will inspect the 
inside of your nose for any signs of bruising or issues that may make collection of the cells from your nose 
difficult.  We will ask you to sit upright and to tilt your head back. We will brush the inside of your nose with a  
Group 1  
will start with the lower 
dose Randomize  
(The computer will 
randomly put you in a 
study  group)  You agree to 
take part in the 
study  Group 2  
will start with the higher 
dose 
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  soft brush to  collect the cells.  We will repeat this procedure for a second brushing.  
• Cheek cell collection  (to determine the change of a cellular substance related to the activity of Avmacol ® in 
previous research , and to determine changes in the shape of the cell’s nu cleus related to tobacco exposure ). This is 
done by rinsing your mouth with tap water for 10 seconds before collection. Each  inner cheek will be brushed 
twice . A collection brush will be scraped  10 times across the inner cheek , then this will be repeated w ith a second 
brush. Then the opposite cheek will be collected in the same manner .  Gentle counter -pressure will be made on 
the outside of your cheeks during these collections.  
• You will be given a sup ply of the study  medication  and instructions on how to take them.  You will be instructed 
to take the Avmacol® tablets with your evening  meal with at least 8 oz of water and with food. Swallow the 
tablets whole, do not crush or chew them. If you miss a dose, do not take a double dose  the next day , just take 
your normal dose the following day . Avmacol® tablets  should be stored in a climate controlled area, away from 
light and moisture and out of reach of children . 
• You will be given a n Intake C alendar to mark each day you take study medication . 
• If you miss the overnight urine collection, you will be asked to collect the overnight urine the night of Visit 2 and 
turn in the urine the next day. A supply of the study medication  will not be provided to you until you have turned 
in your overni ght urine.  
 
You will return to the clinic on Day 4 , 5, 6, 7 or 8 for Visit 3  to undergo the following procedures:  
• A review of your symptom diary  and current medications . 
• You will be asked about your tobacco use since the previous visit.  
• Cheek cell collection.  
• You will be given a urine collection kit to collect an overnight urine sample the night before your next visit to 
bring with you to the visit.  
 
You will return to the clinic at the end of Intervention Period 1 for Visit 4  to undergo the following procedures:  
• You will turn in your overnight urine collection.  
• Return unused study medication  and Intake Calendar.  
• Cheek cell collection.  
• Collection of cells from your nose.  
• Collection of approximately 2½ teaspoons of blood for research tests.  
• A review of your symptom diary  and current medications . 
• You will be asked about your tobacco use since the previous visit.  
• If you miss the overnight urine collection prior to the visit, you will be provided with additional study medication  
and be a sked to continue to take the study medication  the evening of Visit 4 and collect the overnight urine and 
turn in the urine the next day.  
• You will be given a urine collection kit to collect an overnight urine sample the night before your next visit to 
bring  with you to the visit.  
 
After completing  Intervention  Period 1 of study medication, you will undergo a Washout Period  for10 -14 days.  
 
After the Washout Period, you will return to the clinic for Visit 5  to undergo the following procedures  for Intervention 
Period 2 of study medication : 
• You will turn in your overnight urine collection.  
• Cheek cell collection.  
• Collection of cells from your nose.  
• Collection of approximately 2½ teaspoons of blood for research tests.  
• A review of your symptom diary  and current medications . 
• You will be asked about your tobacco use  since the previous visit.  
• Urine pregnancy test if you are a woman who could become pregnant.  
• You will be given a new supply of the study  medication  and an Intake Calendar .  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  As part of this study you will also be asked to answer questions about your tobacco and alcohol use, both before you begin 
the study and again at the End of Intervention visit. Researchers want to see if tobacco and alcohol use affects the side 
effects people might get while on this study, or if tobacco and alcohol use modifies the effects of the study agents.  
 
What possible risks can I  expect from taking part in this study?  
If you choose to take part in this study, there is a risk that you may:  
• Lose time at work or home and spend more time in the hospital or doctor’s office than usual . 
• Be asked sensitive or private questions which you  normally do not discuss , for example about your tobacco and 
alcohol use . There is a risk someone could get access to the personal information in your medical records or other 
information researchers have kept about you. Someone might be able to trace this  information back to you. The 
researchers believe the chanc e that someone will identify you is very small, but the risk may change in the future 
as people come up with new ways of tracing information. In some cases, this information could be used to make i t 
harder for you to get or keep a job. The researchers believe the chance these things will happen is very small, but 
cannot promise that they will not occur.   
 
The Avmacol® used in this study may affect how different parts of your body work, such as your liver, kidneys, heart, 
and blood. The study doctor will be testing your blood and will let you know if changes occur that may affect your health.  
 
There is also a risk that you could have side effects. Here are important points about side effects:  
• The stu dy doctors do not know who will or will not have side effects.  
• Some side effects may go away soon, some may last a long time, or some may never go away.  
 
There is no recognized risk from consuming dietary supplements containing broccoli seed, including Avmacol® . Possible 
mild side -effects might include:  
• flatulence (gas)  
• an unpleasant taste  
• nausea  
These symptoms are not common and have occurred in less than 10% of healthy volunteer s taking  broccoli sprout extracts 
and Avmacol®.  
 
There may be side effects of  Avmacol® that are currently unknown. Everyone taking part in the study will be watched 
carefully for any side effects, including food intolerances.  Tell the study doctor if you notice or feel anything different so 
they can see if you are having a side ef fect. If important new side effects are found, the study doctor will discuss these 
with you.  
 
Here are important points about how you and the study doctor can make side effects less of a problem:  
• Tell the study doctor if you notice or feel anything differe nt so they can see if you are having a side effect.  
• The study doctor may be able to treat some side effects.  
• The study doctor may ask you to stop taking the study medication for several days  to try to reduce side effects.  
 
Reproductive risks:  The effects of this dietary supplement (composed of broccoli seed, broccoli sprout extract, and 
Vitamin C) on the developing human fetus are unknown, however are very unlikely to be harmful. Nonetheless, women 
and men who are able to conceive must agree t o use adequate contraception (hormonal or barrier method of birth control; 
abstinence) for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she 
or her partner is participating in this study, she should in form her study doctor immediately.  
 
Risks of drawing blood:  Possible risks associated with drawing blood are bleeding, bruising, infection, pain, and 
possibly fainting.  
  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  Risks of cell collection:  Possible risks associated with the nose and cheek cell col lection: The brushing of the inside of 
your nose and cheek using a soft brush can cause mild discomfort.  We use a soft brush to obtain the cells from the inside 
of your nose and cheek.  There may be a small amount of bleeding.  If bleeding does occur, gen tle pressure can be used to 
stop the bleeding.  
 
 
What possible benefits can I expect from taking part in this study?  
This study may or may not help you because we do not know how the study drug will compare to the usual approach for 
current smokers . This study may help us learn things that could help people in the future.  
 
Can I stop taking part in this study?  Yes. You can decide to stop at any time. If you decide to stop for any reason, it 
is important to let the study doctor know as soon as possible. If you stop, you can decide whether or not to let the study 
doctor continue to provide your medical information to the organization running the study .  
For the tobacco and alcohol use questions, you can decide to not answer some or all of the questions. Your decision will 
not affect whether you can participate in the study, and it will not affect your relationship with your doctor or the study 
staff.  
The study doctor will tell you about  any new information or changes in the study that could affect your health or your 
willingness to continue in the study.  
 
The study doctor may take you out of the study:  
• If your health changes.  
• If the study is no longer in your best interest.  
• If new information becomes available.  
• If you do not follow the study rules.  
• If the study is stopped early for any reason by the sponsor  (National Cancer Institute) , CIRB (Central Institutional 
Review Board, a group of people who review the research with the goal of protecting the people who take part in 
the study)  or Food and Drug Administration . 
 
What are my rights in this study?  
Taking part in this study is your choice. No matter what decision you make, and even if your decision changes, there will 
be no penalty  to you. You will not lose medical care or any legal rights.  
 
For questions about your rights while in this study, call the ________________________ (insert name of center ) 
Institutional Review Board at  __________________ (insert telephone number ).  
 
What are the costs of taking part in this study?  
The Avmacol®  will be supplied at no charge while you take part in this study. The cost of study -specific exams, tests, and 
any other procedures will be paid for by the study.  
 
You will receive monetary compensati on for study participation. You will receive $25 once you have completed the 
Baseline  visit (Visit 2)  and turned in  your overnight urine collection . You will receive an additional $500 at the end of the 
study upon completion of all required visits and procedures. If you are unable to complete the entire study, the amount of 
compensation will be based on how long you are in the study.  You will receive $50 each for Visits 2 and 3, $100 for Visit 
4, $50 each f or Visits 5 and 6, and $200 for Visit 7. This m oney is to reimburse you for your time and help cover any cost 
you may have in being on the study.  
 
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  What happens if I am injured or hurt because I took part in this study?  
If you feel you have been injured or hurt as a result of taking part in the study, it is important that you tell the study doctor 
immediately. You will get medical treatment if you are injured or hurt as a result of taking part in this study. You and/or 
your health plan will be charged for this treatment.  
The study sponsors  will not offer to pay for medical treatment for injury. Your insurance company may not be willing to 
pay for study -related injury. If you have no insurance coverage, you would be responsible for any costs. Even though you 
are in a study, you keep all of your legal rights to receive payment for injury caused by medical errors.  
 
 
Who will see my medical information?  
Your privacy is very important to us and we will make every effort to protect it. Your information may be given out if 
required by law. For example, cert ain states require doctors to report to health boards if they find a disease like 
tuberculosis. However, we will do our best to make sure that any information that is released will not be able to identify 
you. Some of your health information, and/or inform ation about your specimen, from this study will be kept in a central 
database for research. Your name or contact information will not be put in the database.  
 
There are organizations that may inspect your records. These organizations are required to make s ure your information is 
kept private. Some of these organizations are:  
• The University of Arizona study team including the study doctor and study personnel.  
• The Central Institutional Review Board . 
• The U.S. Food and Drug Administration and the National Cancer Institute . 
• The National Cancer Institute will obtain information from this clinical trial under data collection authority Title 
42 U.S.C. 285.  
 
Where can I get more information?  
You may visit the NCI website at http://cancer.gov/  for more information about studies or general 
information about cancer. You may also call the NCI Cancer Information Service to get the same 
information at: 1 -800-4-CANCER (1 -800-422-6237).  
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov , as required by US law. This website 
will not include information that can identify you. At most, the website will includ e a summary of the results. You can 
search this website at any time.  
 
Who can answer my questions about this study?  
You can talk to the study doctor about any questions or concerns you have about this study or to report side effects or 
injuries. C ontact the study doctor __________________ (insert name of study doctor[ s]) at __________________ (insert 
telephone number ). 
 
ADDITIONAL STUDIES SECTION:  
 
This section is about optional studies you can choose to take part in.  
 
There may be some samples (blood, urine, cheek cells and nose cells ) remaining once the study is complete. The 
researchers would like to store and use your remaining samples for future medical research. The research that may b e 
done is unknown at this time but your samples could hel p researchers to find new ways to prevent, detect, treat, or cure 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  health problems . Some of these studies may be about genes. Genes carry information about features that are found in you 
and in people who are related to you. Researchers are interested in th e way that genes affect how your body responds to 
treatment.  
 
You can take part in the main research study described above without giving your consent for your samples to be stored 
for future research.  
 
WHAT IS INVOLVED?  
If you agree to take part, here is what will happen next:  
1) Your remaining  samples will be stored at t he University of Arizona until the end of the study . 
2) After study completion, y our remaining samples and some related information may be transferred to a central 
facility (Biobank) supporte d by the National Institutes of Health  and stored in the Biobank  along with samples 
and information from other people who take part.  
3) Qualified researchers can submit a request to use the materials stored. A research committee will review each 
request.  There will also be an ethics review to ensure that the request is necessary and proper. Researchers will 
not be given your name or any other information that could directly identify you.   
4) Neither you nor your study doctor will be notified if/when research is conducted using your samples . Neither you 
nor your study doctor will be notified  of the results of the research conducted.   
5) Some of your genetic and health information may be placed in central databases that may be public, along with 
information from many other people. Information that could directly identify you will not be included.  
 
WHAT ARE THE POSSIBLE RISKS?  
1) There is a risk that someone could trace the information in a central database back to you. Even without your 
name or other identifiers, your genetic information is unique to you. The researchers believe the chance that 
someone will identify you is very small, but th e risk may change in the future as people come up with new ways 
of tracing information.  
 
There are laws against the misuse of genetic information, but they may not give full protection. New health 
information about inherited traits that might affect you o r your blood relatives could be found during a study. The 
researchers believe the chance these things will happen is very small, but cannot promise that they will not occur.  
 
A new Federal  law, called  the Genetic  Information  Nondiscrimination  Act (GINA),  generally  makes  it illegal  for 
health  insurance  companies,  group  health  plans,  and most  employers  to discriminate  against  you based  on your 
genetic  information.  This law generally  will protect  you in the following  ways:   
• Health  insurance  companies  and group  health  plans  may not request  your genetic  information  that 
we get from  this research.   
• Health  insurance  companies  and group  health  plans  may not use your genetic  information  when  
making  decisions  regarding  your eligibility  or premiums.   
Employers  with 15 or more  employees  may not use your genetic  information  that we get from  this research  when  
making  a decision  to hire, promote,  or fire you or when  setting  the terms  of your employment.  All health  
insurance  companies  and group  health  plans  must  follow this law by May 21, 2010.  All employers  with 15 or 
more  employees  must  follow  this law as of November  21, 2009.  
   
Be aware  that this new Federal  law does not protect  you against  genetic  discrimination  by companies  that sell life 
insurance,  disability  insurance,  or long-term care insurance.   
 
2) There are laws against the misuse of genetic information, but they may not give full protection. New health 
information about inherited traits that might affect you or your blood relatives could be found during a study. The 
researchers believe the chance these things will happen is very small, but cannot promise that they will not occur.  
  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  HOW WILL INFORMATION ABOUT ME BE KEPT PRIVATE?  
Your privacy is very important to the researchers and they will make every effo rt to protect it. Here are just a few of the 
steps they will take:  
1) When your sample(s) is sent to the researchers, no information identifying you (such as your name or social 
security number) will be sent. Samples will be identified by a unique study code only.  
2) The list that links the unique code to your name will be kept separate from your sample and health information. 
Any Biobank and the University of Arizona staff with access to the list must sign an agreement to keep your 
identity confidential.  
3) Resear chers to whom the University of Arizona study team  sends your sample and information will not know who 
you are. They must also sign an agreement that they will not try to find out who you are.  
4) Information that identifies you will not be given to anyone, un less required by law.  
5) If research results are published, your name and other personal information will not be used.  
 
WHAT ARE THE POSSIBLE BENEFITS?  
You will not benefit from taking part  in the optional studies. The researchers, using the samples from you  and others, 
might make discoveries that could help people in the future.  
 
ARE THERE ANY COSTS OR PAYMENTS?  
There are no costs to you or your insurance. If any of the research leads to new tests, drugs, or other commercial products, 
you will not share in any profits.  
 
WHAT IF I CHANGE MY MIND?  
If you decide you no longer want your samples to be used, you can call the study doctor, _________________,  (insert 
name of study doctor for main trial ) at ________________________  (insert telephone number of study doctor for main 
trial) who will let the researchers know. Then, any sample that remains in the bank will no longer be used. Samples or 
related information that have already been given to or used by researchers will not be returned.  
 
WHAT IF I HAVE MORE QUE STIONS?  
If you have questions about the use of your samples for research, contact the study doctor, _________________,  (insert 
name of study doctor for main trial ) at ________________________  (insert telephone number of study doctor for main 
trial). 
 
Please circle your answer to show whether or not you would like to take part in each option .  
 
SAMPLES  AND INFORMATION  FOR FUTURE RESEARCH STUDIES:  
  
Indicate your choice of “yes” or “no” for each of the following studies.  
 
1.  My remaining samples and relate d information may be kept in a Biobank for use in  future health  research.    
   
Yes     No  
 
2. The information from my tobacco and alcohol use questionnaires may be used in future health research.  
 
        Yes No 
 
3.  I agree that my study doctor, or their  representative, may contact me or my physician to see if I wish to participate in 
other research in the future.  
  
Yes     No  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  4. My genetic data and health information can be released, with no direct identifiers, into scientific databases.   
  
Yes     No  
 
This is the end of the section about optional studies.  
 
My Signature Agreeing to Take Part in the Main Study  
 
I have read this consent form or had it read to me. I have discussed it with the study doctor and my questions have been 
answered. I will be give n a signed copy of this form. I agree to take part in the main study and any additional studies 
where I circled ‘yes’.  
 
 
_____________________________________________________  
Participant’s signature  
 
_____________________________________________________  
Date of signature  
 
_____________________________________________________  
Signature of person(s) conducting the informed consent discussion  
 
 
_____________________________________________________  
Date of signature  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  APPENDIX A  
Karnofsky Performance Status Criteria  
 
 
Karnofsky Performance Scale  
Percent  Description  
100 Normal, no complaints, no evidence of 
disease.  
90 Able to carry on normal activity; minor 
signs or symptoms of disease.  
80 Normal activity with effort; some signs 
or symptoms of disease.  
70 Cares for self, unable to carry on 
normal activity or to do active work.  
60 Requires occasional assistance, but is 
able to care for most of his/her needs.  
50 Requires considerable assistance and 
frequent medical care.  
40 Disabled, requires special care  and 
assistance.  
30 Severely disabled, hospitalization 
indicated. Death not imminent.  
20 Very sick, hospitalization indicated. 
Death not imminent.  
10 Moribund, fatal processes progressing 
rapidly.  
0 Dead.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  APPENDIX B  
Tobacco and  Alcohol Assessment Questionnaires  
  
 TOBACCO ASSESSMENT – BASELINE  
 
REGISTERING INSTITUTION  
 
_________________________________  PARTICIPANT ID  
 
______________________  VISIT TYPE  
 
__________________________  VISIT DATE  
(MM/DD/YYYY)  
___ ___ / ___ ___ / ___ ___ ___ ___  
 
Instructions:  
When a number is requested in the response, please enter a whole number (i.e. “4”) and not a range or fraction of 
a number.  
 
Section A. Basic Cigarette Use Information  
 
1. Have you smoked at least 100 cigarettes (5 packs = 100  cigarettes) in your entire life?  
 
Yes   
 No → Skip to Section B  
 Don’t know/Not sure → Skip to Section B  
 
2. How old were you when you first smoked a cigarett e (even one or two puffs)?  
 
_______ Years old   
 
3. How old were you when you first began smoking cigarettes regularly ?   
 
_______ Years old   
  Check here if you have never smoked cigarettes regularly.  
 
4. How many total years have you smoked (or did you smoke) cigarettes? Do not count any time you may have stayed off 
cigarettes.  
 
______ Years (If you smoked less than one year, write “1.”)   
 
5. On  average when you have smoked, about how many cigarettes do you (or did you) smoke a day?  (A pack usually has 
20 cigarettes in it).   
 
_____ Number of cigarettes per day  
 
6. Do you NOW  smoke cigarettes?  
 
 Everyday  
 Some days  
 Not at all → Skip t o question 8  
 
7.  How soon after you wake up do you smoke your first cigarette?  
 
  Within 30 minutes  
  After 30 minutes  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016   
8. How long has it been since you last smoked a cigarette (even one or two puffs)?   
 
First check which one of the following choices applies to you. Then, if applicable, write a number on the line  
for how many days, weeks, months, or y ears it has been since your last cigarette.  
 
 I smoked a cigarette today (at least one puff)  
 1-7 days → Number of days since last cigarette  ________  
 Less than 1 month → Number of weeks since last cigarette  _________  
 Less than 1 year → Number of mo nths since last cigarette  __________  
 More than 1 year → Number of years since last cigarette  ___________  
 Don’t know/Don’t remember  
 
Section B. Use of Other Forms of Tobacco  
 
9.  Have  you ever used other forms of tobacco, not including cigarettes?  
  
 Yes  
 No → Skip to Section C  
 
10. How often do you/did you use other forms of tobacco?  
 
 Every day → Number of times per day  ________  
 Some days → Number of days _______ per   Week   Month  Year  
 
11. Which of the following products have you ever used regularly ? 
 Check all that apply  
 
 Cigarettes  
 E-cigarettes or other electronic nicotine delivery system  
 Traditional cigars, cigarillos or filtered cigars  
 Pipes  
 Waterp ipe 
 Hookah  
 Clove cigarettes or kreteks  
 Bidis  
 Smokeless tobacco, like dip, chew, or snuff  
 Snus  
 Paan with tobacco, gutka, zarda , khaini  
 Other, Please specify:___________________________  
  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  12. If you do not currently use other forms of tobacco, but did in the past, how long has it been since you last used other 
forms of tobacco regularly?  
 
 Within the past month ( 0 to 1 month ago)  
 Between 1 and 3 months (1 to 3 months ago)  
 Between 3 and 6 months (3 to 6 months  ago) 
 Between 6 and 12 months (6 to 12 months ago)  
 Between 1 and 5 years (1 to 5 years ago)  
 Between 5 and 15 years (5 to 15 years ago)  
 More than 15 years ago  
 Don’t know/Not sure  
 Never used other forms of tobacco regularly  
 
Section C. Second -Hand Smoke Exposure  
 
13. Are you currently living with a smoker?   
 
Yes  
 No  
 
14. In the past 30 days, have you lived  in a place where other people smoked cigarettes indoors?  
 
Yes  
 No  
 
15. In the past 30 days, have you worked  in a place where other people smoked cigarettes indoors?  
 
Yes  
 No  
 
16. Thinking of all your childhood and adult years, have you ever lived  in a place where other people smoked cigarettes 
indoors?  
 
 
 Yes In total, for about how many years?_______ If less than 1, write “1.”   
 No  
 
17. Thinking of all the years you have worked,  have you ever worked  in a place where other people smoked cigarettes 
indoors?   
 
Yes → In total, for about how many years?_______ If less than 1, write “1.”    
 No 
 
Investigator Signature  _______________________________   Date  __ __ / __ __ /  __ __ __ __  
 (MM/DD/YYYY)  
Investigator Name (please print)  __________________________________ _________________  
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  TOBACCO ASSESSMENT - FOLLOW -UP 
 
REGISTERING INSTITUTION  
 
_________________________________  PARTICIPANT ID  
 
______________________  VISIT TYPE  
 
__________________________  VISIT DATE  
(MM/DD/YYYY)  
___ ___ / ___ ___ / ___ ___ ___ ___  
 
Instructions:  
When a number is requested in the response, please enter a whole number (i.e. “4”) and not a range or fraction of 
a number.  
 
1. Do you NOW  smoke cigarettes?  
 
 Everyday  
 Some days  
 Not at all → Skip to Question 3.  
 Never smoked  → Skip to Question 4 
 
 
2. On average, when you smoked, about how many cigarettes do you (or did you) smoke a day? (A pack usually has 20 
cigarettes in it).      
 
_____ Number of cigarettes per day  
 
3. How long has it been since you last smoked a cigarette (even one or two puffs)?    
 
First check which one of the following choices applies to you. Then, if applicable, write a whole number on the line for 
how many days, weeks, months, or years it has been since your last cigarette.  
 
 I smoked a cigarette today (at least one puff)  
 1-7 days → Number o f days since last cigarette ________  
 Less than 1 month → Number of weeks since last cigarette _________  
 Less than 1 year → Number of months since last cigarette __________  
 More than 1 year → Number of years since last cigarette ___________  
 Don’t know/Don’t remember  
 
4. Since your last visit, have you used other forms of tobacco, not including cigarettes?  
 
 Yes 
  No (End)  
 
5. How  often do you/did you use other forms of tobacco?  
 
 Every day → Number of times per day ________  
 Some days → Number of days _______ per   Week   Month  Year  
 
 
 
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  6. Since your last visit, which of the following products have you used ?  Check all that apply  
 
 Cigarettes  
 E-cigarettes or other e lectronic nicotine delivery system  
 Traditional cigars, cigarillos or filtered cigars  
 Pipes  
 Waterpipe  
 Hookah  
 Clove cigaret tes or kreteks  
 Bidis  
 Smokeless tobacco, like dip, chew, or snuff  
 Snus  
 Paan  with tobacco, gutka, zarda , khaini  
 Other, Specify____________________________________________________________________  
 
7. If you do not currently use other forms of tobacco, but did in the past, how long has it been since you last used other 
forms of tobacco regularly?  
 
 Within the past month (0 to 1 month ago)  
 Between 1 and 3 months (1 to 3 months ago)  
 Between 3 and 6 months (3 to 6 months ago)  
 Between 6 and 12 months (6 to 12 months ago)  
 Between 1 and 5 years (1 to 5 years ago)  
 Between 5 and 15 years (5 to 15 years ago)  
 More than 15 years ago  
 Don’t know/Not sure  
 Never used other forms of tobacco regularly  
 
The following instructions pertain to questions 8 - 10.  During each of the following time frames, please indicate 
whether you smoked cigarettes every day, some days, or not at all.  
 
8.  During study treatm ent 
 
 Smoked every day  
 Smoked some days  
 Did not smoke at all  
 Don’t know/not sure  
 Not applicable  
 
9.  After the end of study treatment  
  
 Smoked every day  
 Smoked some days  
 Did not smoke at all  
 Don’t know/not sure  
 Not applicable (I have not completed the study treatment)   
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  10.  Since your last visit to this clinic  
  
 Smoked every day  
 Smoked some days  
 Did not smoke at all  
 Don’t know/not sure  
 
 
 
Investigator Signature _______________________________   Date __ __ / __ __ / __ __ __ __  
 (MM/DD/YYYY)  
Investigator Name (please print) ________________________________________ __________  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  ALCOHOL ASSESSMENT – BASELINE  
 
REGISTERING INSTITUTION  
 
_________________________________  PARTICIPANT ID  
 
______________________  VISIT TYPE  
 
__________________________  VISIT DATE  
(MM/DD/YYYY)  
___ ___ / ___ ___ / ___ ___ ___ ___  
 
Instructions:  
For the following questions about drinking alcoholic beverages, a drink means a 12 oz. beer, a 5  oz. glass of wine, 
or one and a half ounces of liquor .  
When a number is requested in the response, please enter a whole number (i.e. “4”) and not a range or f raction of 
a number.  
 
1. In your entire life, h ave you  had at least 12 drinks of any kind of alcoholic beverage?   
 
 Yes 
 No (End)  
 Refused (End)  
 Don’t know /Not sure  
 
2. In the past 12 months, on average, how often did you drink any type of alcoholic beverage?  
 
________ (Enter the number of days you drank based on the timeframe checked below.  Enter 0 if you never drank 
and skip to Question 6. )  
 Week  
 Month  
 Year  
 Refused  
 Don’t know /Not sure  
 
3. In the past 12 months, on those days that you drank alcoholic beverages, on average, how  many drinks   
did you have per day?  
________ (Enter the average number of drinks per day)  
 
 Refused  
 Don’t know /Not sure  
 
4. In the past 12 months, on how many days did you ha ve 5 or more drinks of any alcoholic beverage?  
 
_________ (Enter the number of days you had 5 or more drinks, or enter 0 if none .) 
 
 Refused  
 Don’t know /Not sure  
 
5. Was there ever a time or times in your life when you drank 5 or more drinks of any kind of alcoholic beverage almost 
every day?  
 
 Yes 
 No  
 Refused  
 Don’t know /Not sure  
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  6. If you do not currently drink alcoholic beverages, but did in the past, how long has it been since  
you last drank regularly?   
 
 Within the past month (0 to 1 month ago)  
 Between 1 and 3 months (1 to 3 months ago)  
 Between 3 and 6 months (3 to 6 months ago)  
 Between 6 and 12 months (6 to 12 months ago)  
 Between 1 and 5 years (1 to 5 years ago)  
 Between 5 and 15 years (5 to 15 years ago)  
 More than 15 years ago  
 Don’t know/Not sure  
 Never drank regularly  
 
7. At the heaviest point, either now or in the past, on the days when you drank, about how many drinks did you drink  a 
day on the average?  
 
__________ (Enter the number of drinks  a day)  
  
 Refused  
 Don’t know/Not sure  
 
8. How many years have you  been drinking (or did drink) regularly?  
 
______ years  
 
 Refused  
 Don’t know/Not sure  
 
9. At what age did you begin drinking regularly?  
 
______ years of age   
 
 Refused  
 Don’t know/Not sure  
 
10. What type(s) of alcohol do you drink? (Mark ALL  that apply)  
 
 Wine  
 Liquor  
 Beer  
 Wine cooler  
 
 
Investigator Signature _______________________________   Date __ __ / __ __ / __ __ __ __  
 (MM/DD/YYYY)  
Investigator Name (please print) __________________________________ ________________  
 
 
 
    
  UAZ2017 -09-02 
  Protocol Version 3 Amendment 6, 10.17.18 
 
DCP Protocol Template Version 8.5  
08/31/2016  ALCOHOL ASSESSMENT  - FOLLOW -UP 
 
REGISTERING INSTITUTION  
 
_________________________________  PARTICIPANT ID  
 
______________________  VISIT TYPE  
 
__________________________  VISIT DATE  
(MM/DD/YYYY)  
___ ___ / ___ ___ / ___ ___ ___ ___  
 
Instructions:  
 
For the following questions about drinking alcoholic beverages, a drink means a 12 oz. beer, a 5  oz. glass of wine, 
or one and a half ounces of liquor .  
When a number is requested in the response, please enter a whole number (i.e. “4”) and not a range or f raction of 
a number.  
 
1. During the past 30 days, did you drink any alcoholic beverage s?  
 
 Yes 
 No (End) 
 Refused (End)  
 Don’t know/Not sure 
 
2. During the past 30 days , how many days per week or per month did  you drink any alcoholic beverages, on the average?   
 
________ (Enter number of days you drank based on the timeframe checked below.  Enter 0 if you did not drink.)  
 
 Week  
 Month  
 Refused  
 Don’t know /Not sure  
 
3. On the days when you drank, on average, about how many drinks did you have ?  
 
________ (Enter the average number of drinks you had per day.)  
 
 Refused  
 Don’t know /Not sure  
 
4. In the past 30 days, on how many days did you have 5 or more drinks per day?  
 
_____________  (Enter the number of days you had 5 or more drinks, or enter 0 if none .)  
 
 Refused  
 Do not know/Not sure  
 
 
Investigator Signature _______________________________   Date __ __ / __ __ / __ __ __ __  
  (MM/DD/YYYY)  
Investigator Name (please print) __________________________________ _________________  